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A B S T R A C T
Background
Despite advances in chemotherapy, prognosis of ovarian cancer remains poor. Antigen-specific active immunotherapy aims to induce
tumour-antigen-specific anti-tumour immune responses as an alternative treatment for ovarian cancer.
Objectives
To assess the feasibility of antigen-specific active immunotherapy for ovarian cancer. Primary outcomes are clinical efficacy and antigen-
specific immunogenicity with carrier-specific immunogenicity and side effects as secondary outcomes.
Search methods
For the previous version of this review, a systematic search of the Cochrane Central Register of Controlled Trials (CENTRAL) 2009,
Issue 3, Cochrane Gynaecological Cancer Group Specialized Register, MEDLINE and EMBASE databases and clinicaltrials.gov was
performed (1966 to July 2009). We conducted handsearches of the proceedings of relevant annual meetings (1996 to July 2009).
For this update of the review the searches were extended to October 2013.
Selection criteria
Randomised controlled trials (RCTs), as well as non-randomised non-controlled studies that included participants with epithelial
ovarian cancer, irrespective of stage of disease, and treated with antigen-specific active immunotherapy, irrespective of type of vaccine,
antigen used, adjuvant used, route of vaccination, schedule, and reported clinical or immunological outcomes.
Data collection and analysis
Two reviews authors independently performed the data extraction. Risk of bias was evaluated for RCTs according to standard method-
ological procedures expected by The Cochrane Collabororation or for non-RCTs using a selection of quality domains deemed best
applicable to the non-randomised non-controlled studies.
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Main results
Fifty-five studies were included (representing 3051 women with epithelial ovarian cancer). Response definitions showed substantial
variation between trials, which makes comparison of trial results unreliable. Information on adverse events was frequently limited.
Furthermore, reports of both RCTs and non-RCTs frequently lacked the relevant information necessary to assess risk of bias. Serious
biases in most of the included trials can therefore not be ruled out.
The largest body of evidence is currently available for CA-125 targeted antibody therapy (16 studies: 2339 participants). Non-RCTs of
CA-125 targeted antibody therapy suggests increased survival in humoral and/or cellular responders. However, four large randomised
placebo-controlled trials did not show any clinical benefit despite induction of immune responses in approximately 60% of participants.
Other small studies targeting many different tumour antigens showed promising immunological results. As these strategies have not
yet been tested in RCTs, no reliable inferences about clinical efficacy can be made. Given the promising immunological results, limited
side effects and toxicity exploration of clinical efficacy in large well-designed RCTs may be worthwhile.
Authors’ conclusions
We conclude that despite promising immunological responses, no clinically effective antigen-specific active immunotherapy is yet
available for ovarian cancer. Results should be interpreted cautiously as there was a significant lack of relevant information for the
assessment of risk of bias in both RCTs and non-RCTs.
P L A I N L A N G U A G E S U M M A R Y
Antigen-specific active immunotherapy for ovarian cancer
Background
Ovarian cancer is the leading cause of death from gynaecological cancers. Standard therapy consists of surgery and chemotherapy.
Responses to chemotherapy are generally good, however, themajority of women will relapse, for which no curative treatment is available.
The presence of certain immune cells in tumours is associated with longer survival. This suggests that stimulation of anti-tumour
immune responses, i.e. immunotherapy, might be a useful approach to improve outcome for women with ovarian cancer.
Review question
In this review, the feasibility of antigen-specific active immunotherapy is evaluated. Antigen-specific active immunotherapy aims at the
induction of anti-tumour immune responses through the administration of a tumour-antigen, a molecule that is expressed by tumour
cells and hardly expressed by healthy cells. Information on clinical outcome, immunological responses, and side effects was collected.
Main findings
Fifty-five studies, which included 3051 women with ovarian cancer were identified, published between 1966 and 2013. The most
frequently described strategy was administration of antibodies targeting the tumour antigen CA-125 (2339 participants in 16 studies).
Most of these primarily evaluated safety and immunological responses. Severe flu-like and gastrointestinal symptoms occurred in 7%
to 30% of participants. Antibodies and immune cells recognising the tumour antigen CA-125 were frequently detected, albeit response
rates varied between studies. Despite these promising immunological responses, no survival advantage for participants treated with CA-
125 directed antibody compared to placebo was found in four large studies.
For strategies not relying on antibody administration, similar conclusions cannot be drawn as immune system to the vaccine. Overall,
treatment was well-tolerated, with inflammatory side effects at injection site most frequently reported. Responses of the immune system
were observed for most strategies studied, but their clinical benefit still has to be evaluated in large trials.
Quality of the evidence and conclusions
Because there is currently no high-quality evidence of clinical benefit, antibody therapy targeting CA-125 should in its current form
not be incorporated in standard treatment.
Based on a lack of uniformity in included studies, we strongly advocate universal adoption of response definitions, guidelines for adverse
events reporting, and directives for trial conduct and reporting. Furthermore, results from ongoing RCTs are awaited and further RCTs
should be conducted.
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B A C K G R O U N D
Description of the condition
Ovarian cancer is the sixth most common cancer and the seventh
cause of death from cancer in women worldwide (Parkin 2006). It
is the second most common gynaecological cancer and the leading
cause of death from gynaecological cancers in the Western world.
As the majority of ovarian malignancies (80% to 90%) arise from
the epithelium, all statements in the remainder of this review about
ovarian cancer apply to epithelial ovarian cancer only. Worldwide
age-standardised incidence rates range from 2.6 per 100,000 in
Northern Africa to 13.3 per 100,000 in Northern Europe (Parkin
2006).
Stage of disease at presentation is the most important prognostic
factor. Due to the asymptomatic course of the disease, themajority
of participants have extensive disease at presentation (stage III
to IV according to FIGO classification (Benedet 2000)). Despite
standard treatment, which consists of cytoreductive surgery and
platinum-based chemotherapy, almost all women with advanced
stage disease at presentationwill relapse, with amedian progression
free survival (PFS) of only 18 months. When residual or recurrent
disease manifests itself, resistance to chemotherapy often prohibits
further curative therapy, resulting in a disease specific five-year
survival for women with advanced stage ovarian disease of only
10% to 20% (Agarwal 2006; Thigpen 2000).
Description of the intervention
The immune system seems to play a role in ovarian cancer. This is
reflected in the observation that in more than half of women with
ovarian cancer, T- cells are presentwithin tumour-islets (Raspollini
2005; Zhang 2003).Women with advanced ovarian cancer, whose
tumour is infiltrated by these T-cells, have a better clinical out-
come compared to women without these tumour-infiltrating T-
cells (Dong 2006; Raspollini 2005; Zhang 2003). More specif-
ically, higher numbers of cytotoxic T-cells, which can directly
recognise and kill tumour cells, and increased ratios between cyto-
toxicT-cells (CD8+) andhelperT-cells (CD4+)within the tumour
epithelium are associated with improved survival (Sato 2005).
Immunotherapy is one of the novel therapeutic strategies under
investigation for ovarian cancer. It aims to induce or enhance active
immune responses directed towards the tumour and to consolidate
anti-tumour effects of standard therapy, delay and possibly prevent
progression of disease. More specifically, antigen-specific active
immunotherapy aims at activation of the adaptive immune system
directed towards a specific target antigen through administration
of a molecular defined antigen-specific vaccine to the patient.
How the intervention might work
An antigen is a molecule, usually a protein or polysaccharide,
which can stimulate an immune response. Tumour antigens can
be subdivided into different categories such as mutated self pro-
teins, products of oncogenes (e.g. Her-2/Neu), mutated tumour
suppressor genes (e.g. p53), and aberrantly expressed self proteins
(e.g. sperm protein 17, MAGE-1). Numerous tumour-associated
antigens are known in ovarian cancer. To obtain a tumour-spe-
cific immune response, immunotherapy exploits the differential
expression of antigens between normal and tumour cells. A ma-
jor challenge concerning the safety of immunotherapy lies in the
prevention of auto-immunity i.e. induction of immune cells that
preferentially recognise and kill tumour cells, but avoid destruc-
tion of normal body cells. From a theoretical point of view, other
possible side effects include allergic reactions to components of
the vaccine and inflammatory reactions at the site of injection.
Why it is important to do this review
Several immunotherapeutic strategies are now being employed us-
ing different tumour antigens. These studies have, however, gen-
erally not yet evolved past phase I/II studies. To our knowledge,
no systematic review of antigen-specific active immunotherapy in
ovarian cancer has been carried out so far.
The immunogenicity and clinical efficacy of antigen-specific ac-
tive immunotherapy in ovarian cancer is evaluated in this review. A
systematic review about this topic is useful to ascertain the achiev-
ability of this treatment modality for ovarian cancer.
O B J E C T I V E S
The primary objective of this review was to assess the efficacy
(i.e. clinical and/or immunological responses) of antigen-specific
active immunotherapy for the treatment of ovarian cancer. The
secondary objective was to establish which immunotherapeutic
strategies combined with which tumour antigens provide the best
immunological and clinical results.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We anticipated that there would be no randomised controlled
trials (RCTs) on this subject. Therefore we also included phase I,
3Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
phase II non-randomised andnon-controlled and if available phase
III studies. We realised that results from non-randomised, non-
controlled studies cannot readily be extrapolated to the general
population. Nevertheless, we felt that given the anticipated lack
of RCTs, inclusion of these studies into this review was justifiable.
Types of participants
Women diagnosed with epithelial ovarian cancer, irrespective of
stage of disease. However, as patient populations may differ sub-
stantially between different types of studies to be included in this
review, for each study we documented what type of person was
included into the study (e.g. women with end-stage disease or
women with residual disease).
Because we anticipated that there would not be many studies that
included women with ovarian cancer only, we also included im-
munotherapeutic studies in people with cancer that included at
least two women with ovarian cancer; with the additional require-
ment that the results for these individual women were separately
identifiable from the study publication or communication with
the author, and only data on these women were extracted for the
review. We were fully aware of the vigilance necessary when draw-
ing conclusions based on studies with such small numbers, but felt
that given the anticipated lack of large RCTs, inclusion of these
studies into this review was justifiable.
Types of interventions
Antigen-specific active immunotherapy is defined as therapy that
aims at inducing an adaptive immune response directed towards
the tumour by means of administration of a specific well-defined
tumour antigen.We compared interventionswith each other based
on the above-mentioned characteristics.
We included all interventions that aimed at antigen-specific active
immunotherapy irrespective of type of vaccine, antigen used, ad-
juvant used, route of vaccination, vaccination schedule.
Types of outcome measures
Primary outcomes
Clinical efficacy
To assess clinical efficacy we evaluated the following:
1. Tumour responses to immunotherapy (complete/partial re-
sponse, stable/progressive disease), as measured by:
• CA-125 levels according to or transposable to Gynecologic
Cancer Intergroup (GCIG) criteria (Rustin 2004);
• tumour response according to WHO criteria (WHO 1979)
or Response Evaluation Criteria in Solid Tumors Group
(RECIST) criteria (Therasse 2000).
2. If available, we evaluated responses to post-immunotherapy
treatment, as there are indications that people with small cell lung
cancer treated with chemotherapy after immunotherapy have in-
creased survival as opposed to people who did not receive im-
munotherapy (Antonia 2006).
3. If available, survival differences based on treatment with im-
munotherapy.
Antigen-specific immunogenicity
We recorded the number of observed antigen-specific humoral and
cellular responses.Whenpossible, we separately reported responses




As certain immunotherapeutic strategies rely on the use of carriers
that may be the subject of an immune response besides the in-
tended antigen-specific immune response, we recorded informa-
tion on the induction of carrier-specific immune responses when
appropriate.
Adverse events
To obtain information on the toxicity of antigen-specific im-
munotherapy, we extracted data on adverse events observed and
reported in the different studies. Adverse events were categorised as
local adverse events at the site of immunisation or systemic adverse
events (all other reported adverse events). Systemic adverse events
were subdivided into autoimmunity, allergic reactions and other
adverse events occurring after immunisation. If sufficient infor-
mation was available, adverse events were classified according to
the Common Terminology Criteria for Adverse Events (CTCAE
2009).
Search methods for identification of studies
For the original review (Leffers 2010), we searched the Cochrane
Central Register of Controlled Trials (CENTRAL) 2013, Is-
sue 9 (Appendix 1) and the Cochrane Gynaecological Cancer
Group Specialized Register in October 2013. Furthermore, we
also searched MEDLINE (1966 to July 2009) (Appendix 2)
and EMBASE (1974 to July 2009) (Appendix 3) according to
the search strategies listed, well as the prospective trial register
www.clinicaltrials.gov.
Handsearcing was undertaken of abstracts in the proceedings of
annualmeetings of Society ofGynecologicOncologists, the Amer-
ican Association for Cancer Research and the International Soci-
ety for Biological Therapy of Cancer (1996 to July 2009). The
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International Society for Biological Therapy of Cancer has been
renamed the Society for Immunotherapy of Cancer (SITC), thus
we also searched the proceedings of the annual meeting of SITC.
For this update of the review the searches were extended up to
October 2013.
The bibliography of each primary reference and of recent reviews
of immunotherapy for ovarian cancer was checked for additional
study publications. In addition, we wrote to specialists involved
in research regarding immunotherapy for ovarian cancer for in-
formation about the results of unpublished or ongoing studies.
Relevant data were included in this review.
There were no language restrictions other than those inherent to
the databases surveyed.
Data collection and analysis
Selection of studies
We downloaded all titles and abstracts retrieved by electronic
searching to ReferenceManager, duplicates were removed and two
review authors (HWN and NL) independently examined the re-
maining references. Those studies which clearly did not meet the
inclusion criteria were excluded and copies of the full text of po-
tentially relevant references were obtained. Two review authors
(HWN and NL) independently assessed the eligibility of retrieved
papers. We resolved differences by discussion or by appeal to a
third review author (TD) if necessary. We documented reasons for
exclusion.
Data extraction and management
Two review authors (HWN andNL) independently extracted data
on characteristics of participants and interventions, study quality
and endpoints for included studies, onto a data extraction form
specially developed for the review (Appendix 4).
Where data on clinical efficacy and antigen-specific immunogenic-
ity were missing from reports, we attempted to contact the authors
to obtain the missing information. A third review author (WH or
TD) checked the results.
Assessment of risk of bias in included studies
We assessed the risk of bias in RCTs by means of The Cochrane
Collaboration’s ’Risk of bias’ tool.
No standard tools to evaluate validity are available for non-RCTs.
Instead, for these studies we evaluated the risk of bias using the
following four domains (Table 1):
• sample definition and selection
◦ clear definition of inclusion/exclusion criteria
◦ representative selection





◦ specifications of outcome measures
◦ relevance of outcome measures
◦ reporting of outcome measures
• statistical analysis:
◦ adequate rationale for number of participants included
◦ adequate description withdrawal/exclusion during the
study
◦ adequate presentation of results.
These domains were selected as representative for, and applicable
to, non-randomisednon-controlled studies froma list of 12quality
domains and items deemed to be pivotal to the assessment of non-
RCTs (Deeks 2003).
Two review authors (HWN and NL) carried out the ’Risk of bias’
assessment. We resolved any discrepancies by discussion; if neces-
sary we consulted a third author (WH or TD).
Data synthesis
This review provides a narrative analysis, because the included
studies are highly heterogenous regarding intervention and out-
come measures. Furthermore, data in publications were often pre-
sented with insufficient details (lack of standard deviations (SDs)
or only some of the multiple outcomes presented), and additional
information from report authors was difficult to obtain. Therefore
we felt that quantitative meta-analysis and calculation of effect size
estimates would neither be meaningful nor appropriate in this re-
view. We limited analysis to a structured summary and discussion
of available studies and findings.
R E S U L T S
Description of studies
Results of the search
Initial version of review
From the electronic searches of MEDLINE and EMBASE, 56
out of 311 abstracts were selected as potentially compliant with
the selection criteria and full texts were retrieved. Evaluation of
the retrieved full texts resulted in the exclusion of 26 papers (see
Excluded studies). In addition to the 30 selected full texts, another
14 abstracts were identified by handsearching the proceedings of
the periodic meetings specified in the methods section. Study au-
thors were contacted for manuscripts, but no full texts were ob-
tained for these abstracts. Together the 44 selected full texts and
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meeting abstracts described a total of 35 studies. Search of the
prospective trial register www.clinicaltrials.gov resulted in identi-
fication of an additional 26 studies. For only four of these could a
full text or meeting abstract be retrieved and only one study com-
plied with our inclusion criteria (Sabbatini 2007). The remaining
studies were either ongoing (n = 15) or completed but not yet
published (n = 6). Search of CENTRAL (2009, Issue 3) did not
identify any additional studies. Thus, a total of 36 studies were
included in this review. Generally, the most recent peer-reviewed
publication was selected as the primary reference.
First update of review
For the update of the review, the electronic searches ofMEDLINE
and EMBASE resulted in an additional 23 included papers and
10 excluded papers (Characteristics of excluded studies). For five
studies in the previous version of this review, a full text publi-
cation, update or additional paper was now available. Search of
CENTRAL (2013, Issue 3) did not yield any additional studies.
Search of clinicaltrials.gov resulted in two additional published
studies. Futhermore, 26 relevant studies without available results
were identified (Characteristics of ongoing studies). Twelve studies
are currently recruiting participants, four studies are ongoing but
not recruiting, nine studies are classified as completed and for two
studies status is unknown. Overall, an additional 19 studies were
included in the update of this review resulting in a total number
of 55 included studies involving 3051 women (Characteristics of
included studies).
Included studies
The 55 studies included in this updated review were all published
in English (Characteristics of included studies, Table 2).
Design
As we expected the majority of studies were uncontrolled phase
I or II studies (43 out of 55). Only four studies were ran-
domised placebo-controlled studies (Berek 2001; Berek 2004;
Berek 2009; Sabbatini 2013). Randomised allocation of partici-
pants to different regimens was used in eight studies (Baumann
2011; Braly 2009; Chu 2012; Freedman 1998; Goh 2013; Heiss
2010; Method 2002; Sabbatini 2006). In four studies the im-
munogenicity of a previously applied immuno scintigraphic agent
was retrospectively studied (Möbus 2003;Noujaim 2001; Schultes
1998; Wagner 1993).
Sample sizes
The median number of women with epithelial ovarian cancer
treated per study was 20 (range 2 to 888). Nineteen studies
included less than 10 participants. Seventeen studies also in-
cluded participants with other types of cancer (Berinstein 2012;
Brossart 2000; Dhodapkar 2012; Gribben 2005; Gulley 2008;
Heiss 2010; Kaumaya 2009; Le 2012; Letsch 2011; Mohebtash
2011; Morse 2011; Odunsi 2012; Ohno 2009; Peethambaram
2009; Sandmaier 1999; Ströhlein 2009; Tsuda 2004). A sam-
ple size calculation or rationale was provided for 13 studies only
(Baumann 2011; Berek 2004; Berek 2009; Braly 2009; Gribben
2005; Heiss 2010; Leffers 2009a; Rahma 2012; Sabbatini 2006;
Sabbatini 2007; Sabbatini 2012; Sabbatini 2013; Vermeij 2012).
Participants
As was expected, the disease status at study entry varied largely
between studies (Table 2). Participants with evidence of resid-
ual or recurrent disease after treatment were most frequently in-
cluded (27 out of 55) (Baumann 2011; Brossart 2000; Ehlen
2005; Galanis 2010; Gordon 2004; Gribben 2005; Gulley 2008;
Heiss 2010; Kaumaya 2009; Le 2012; Leffers 2009a; MacLean
1992;MacLean 1996; Möbus 2003;Mohebtash 2011; Nicholson
2004; Noujaim 2001; Peethambaram 2009; Ströhlein 2009; van
Zanten-Przybysz 2002; Vermeij 2012).Six studies included par-
ticipants with and without evidence of disease after prior therapy
(Berinstein 2012; Braly 2009; Chianese-Bullock 2008; Odunsi
2007; Sabbatini 2006; Tsuda 2004). Fourteen studies included
participants with complete response to therapy for primary or re-
current disease (Berek 2001; Berek 2004; Berek 2009; Chu 2012;
Diefenbach 2008; Goh 2013; Imhof 2013; Morse 2011; Odunsi
2012; Rahma 2012; Sabbatini 2000; Sabbatini 2007; Sabbatini
2012; Sabbatini 2013). In one study, treatment was administered
together with adjuvant chemotherapy after primary cytoreductive
surgery (Braly 2009). For the remaining 14 studies disease sta-
tus at entry was not reported (Berinstein 2013; Dhodapkar 2012;
Freedman 1998; Letsch 2011;Ma2002;Method2002;Nishikawa
2006; Ohno 2009; Pfisterer 2006; Reinartz 2004; Sandmaier
1999; Schultes 1998; Takeuchi 2013; Wagner 1993).
Interventions
Themajority of studies described antibody therapy (21 out of 55),
usually targeting CA-125 (16 (2339 women) out of 21). Most
studies included only one target antigen in the vaccine, but in 10
studies multiple antigens were simultaneously targeted (Berinstein
2012; Chianese-Bullock 2008; Chu 2012; Gulley 2008; Imhof
2013; Mohebtash 2011; Morse 2011; Sabbatini 2007; Takeuchi
2013; Tsuda 2004). Antibodies were usually administered intra-
venously (12 out of 21). For other vaccine types, subcutaneous
injections were most common (21 out of 34).
Concurrent treatment with immunomodulatory drugs was not al-
lowed in 15 out of 55 studies. In an additional 20 studies, con-
comitant immunomodulatory agents were not part of the studied
intervention, but no explicit statements were made about prohi-
bition of such drugs in the protocol. In 18 studies immunomodu-
latory drugs were part of the protocol (i.e. carboplatin-paclitaxel,
cyclophosphamide, IL-2 +/- GM-CSF, TLR agonists poly-ICLC
or resiquimod, or diphenhydramine) and one of these allowed
interruption of immunotherapy by chemotherapy for progressive
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disease (Reinartz 2004). Furthermore, two retrospective studies
explicitly mentioned that concurrent chemotherapy was allowed
at the discretion of the treating clinician (Möbus 2003; Wagner
1993).
Outcomes
Information on immunological responses, clinical responses, sur-
vival and adverse events was available for 51, 35, 37 and 45 studies
respectively.
Excluded studies
A summary of the excluded studies is given in the table of
Characteristics of excluded studies. Frequent reasons for exclusion
were inclusion of too few participants with ovarian cancer and the
impossibility to distinguish results of women with ovarian cancer
from other study participants.
Risk of bias in included studies
Weevaluated risk of bias usingTheCochraneCollaboration’s ’Risk
of bias’ tool. Results of individual studies (both RCT and non-
RCT) are available in the table of Characteristics of included
studies. For RCTs, assessment of risk of bias was hindered by the
fact that for four of the 12 RCTs only meeting abstracts were
available. The eight trials, for which we could retrieve full texts,
also did not report on some of the items of the ’Risk of bias’ tool.
With this substantial lack of information, it is highly likely that
included studies are subject to biases and difficult to make any
statements about the validity of the included RCTs (Figure 1).
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies. The high risk of selection bias in the majority of included studies is a
reflection of the high number of uncontrolled studies in this review. The risk of the remaining biases could not
be adequately judged for the included uncontrolled studies, thus explaining the large percentage of missing
risk assessments.
In addition to the ’Risk of bias’ tool, we evaluated non-RCTs ac-
cording to the checklist provided in Table 1. An overview of the
results is provided in Table 3. Important observations from this
table are the lack of clearly defined in-/exclusion criteria in 13
out of 43 studies combined with the serious under-reporting of
baseline characteristics (29 out of 43 studies), which makes it im-
possible to evaluate whether the study populations were represen-
tative of the true population. Although the investigational inter-
ventions were well described in the majority of studies (39 out of
43), information on the allowance or application of concomitant
immunomodulatory treatment was frequently absent (21 out of
43). Albeit a clear description of outcome measures was available
for 29 studies, an adequate calculation of sample size based on a
clearly defined primary outcome measure was available for only
five studies. Furthermore, the applied checklist shows that the jus-
tification of withdrawals and exclusions during the study, as well
as the presentation of study results are items that require serious
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attention in the reports of these non-randomised studies.
Based on the above, the risk of bias in the studies included in this
systematic review cannot be neglected. Especially selection bias
(selection of a treatment population not comparable to control
group or true population), attrition bias (inadequate reporting of
withdrawal and exclusions during the study resulting in possible
over- or underestimation of effect) and selective reporting bias are
likely to affect the studies included in this review. The effects of
interventions described below must therefore be interpreted with
prudence.
Allocation
As can be deduced from the Characteristics of included studies
table, we were unable to identify themethod of randomisation and
allocation for several randomised studies, which means that we
cannot rule out a selection bias for these studies. For the remaining
RCTs, selection bias does not seem likely.
The majority of included studies however were early phase non-
randomised studies with only a single study arm. Selection bias
in these studies may have occurred in several ways: 1) selective
inclusion of patients with no other treatment options due to end-
stage disease, at which point, function of the immune system may
also be seriously impaired, thus resulting in an underestimation of
immunogenicity and possible clinical benefit of a given vaccine, or
2) selective recruitment of fairly immunocompetent patients with
no evidence of disease, resulting in a possible overestimation of
immunogenicity and possible clinical benefit of a given vaccine.
Blinding
Inherent to the study design, no blinding of patients or treating
(study) physicians was performed in any of the non-RCTs. All of
the participantsmay have hadbenefit from the additional attention
awarded to them as participants in a study, and performance bias
may thus have influenced the results of these studies. Furthermore,
it is unclear whether for these studies, outcome assessors were
aware of the clinical condition of patients, thus detection bias may
have occurred in these studies.
Blinding of participants, care givers and/or outcome assessors was
described in four RCTs only, all comparing antibody therapy
versus placebo (Berek 2001; Berek 2004; Berek 2009; Sabbatini
2013). The other RCTs compared dosage levels (Baumann 2011;
Freedman 1998), administration route (Sabbatini 2006), number
of gifts of a given drug (Method 2002), timing of the intervention
in relation to standard chemotherapy (Braly 2009), addition of
a immunomodulatory drug (Chu 2012), or immunotherapeutic
intervention compared with standard of care (Goh 2013; Heiss
2010). Given these study designs, we feel that for most of these
studies, the risk of performance bias is low. Information on blind-
ing of outcome assessors was frequently missing. The risk of de-
tection bias can therefore not be reliably judged.
Incomplete outcome data
Only one RCT was deemed to have a high risk of attrition bias
based on the differences in withdrawals between groups (Heiss
2010). Risk of attrition bias was unclear for five other RCTs (Berek
2001; Freedman 1998; Goh 2013;Method 2002; Sabbatini 2006)
and deemed low for the remaining RCTs (Baumann 2011; Berek
2004; Berek 2009; Braly 2009; Chu 2012; Sabbatini 2013).
Selective reporting
None of the included studies had a publicly available registered
study protocol. It is therefore unclear whether studies selectively
reported outcomes.
Other potential sources of bias
Given the elapsed time since publication of the meeting abstract,
a publication bias is likely to exist for two out of three RCTs
for which only a meeting abstract was available (Berek 2001;
Freedman 1998). Study completion for the third RCT with only






Clinical responses to therapy were evaluated in 34 studies (Table
4). In the reports on these studies, criteria for evaluation and/
or explicit description of tumour responses per participant as
well as the time point at which the evaluation took place were
frequently not available. For studies that did mention evalua-
tion of tumour responses, response outcomes were based on ei-
ther CA-125 levels combined with tumour imaging (Baumann
2011; Chianese-Bullock 2008; Chu 2012; Diefenbach 2008;
Ehlen 2005; Galanis 2010; Gordon 2004; Gulley 2008; Leffers
2009a; Ohno 2009; Rahma 2012; Sabbatini 2006; Ströhlein
2009; Tsuda 2004; van Zanten-Przybysz 2002; Vermeij 2012),
CA-125 alone (Nicholson 2004; Wagner 1993) or imaging alone
(Le 2012; Odunsi 2007; Peethambaram 2009; Reinartz 2004;
Sabbatini 2012; Takeuchi 2013). Only 11 studies explicitly men-
tioned evaluation of imaging according to the internationally ac-
ceptedWHO or RECIST criteria (Baumann 2011; Galanis 2010;
Le 2012; Leffers 2009a;Ohno 2009; Rahma 2012; Reinartz 2004;
Sabbatini 2012; Takeuchi 2013; Tsuda 2004; Vermeij 2012) and
only five studies evaluated CA-125 levels according to GCIG
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criteria or described CA-125 levels in such a way that evalua-
tion according to these criteria was possible for at least some
participants (Baumann 2011; Galanis 2010; Leffers 2009a; van
Zanten-Przybysz 2002; Vermeij 2012). Strikingly, eight stud-
ies stated that evaluation of tumour responses was performed,
but results could not be found in the publications (Diefenbach
2008;Dhodapkar 2012;Gulley 2008; Imhof 2013;Method 2002;
Odunsi 2007; Reinartz 2004; Wagner 1993). Complete or par-
tial tumour responses in participants with evidence of disease at
study entry were reported by only four studies (Baumann 2011;
Gordon 2004; Odunsi 2007; Takeuchi 2013) in a small fraction
of participants. These results need to be interpreted with caution
as criteria for response evaluation were not defined by two of these
studies (Gordon 2004; Odunsi 2007).
Responses to ’secondary’ treatment after immunotherapy
Although studies generally have a period of follow-up to obtain
information on survival, in the majority of studies no report is
given of subsequent treatment with and response to secondary
chemotherapy.Nine studiesmention that participantswere treated
with chemotherapy after immunotherapy (Berek 2004; Gordon
2004; Gribben 2005; Leffers 2009a; Möbus 2003; Odunsi 2007;
Reinartz 2004; Ströhlein 2009; van Zanten-Przybysz 2002), but
only four studies report response to secondary chemotherapy in
relation to immunological responses to immunotherapy (Gordon
2004; Gribben 2005; Leffers 2009a; Reinartz 2004).
In a preliminary report, clinical responses of 28 out of 42 par-
ticipants treated with chemotherapy for clinically relevant pro-
gression during or after antibody therapy were reported in con-
junction with the induction of human-anti-mouse and anti-anti-
idiotype antibodies. Although both participants with a complete
response had strong humoral responses, similar or stronger anti-
body responses were also observed for participants with stable or
progressive disease (Reinartz 2004). In another study, shortly af-
ter monotherapy with a monoclonal antibody, 13 out of 20 par-
ticipants received chemotherapy combined with the monoclonal
antibody. In this study, clinical responses to chemo-immunother-
apy were only observed in participants with cellular responses to
CA-125 and/or autologous tumour (Gordon 2004). A study of
synthetic long peptides targeting p53 did not show any improve-
ment of survival or tumour responses to secondary chemotherapy
(Leffers 2009a). Finally, the authors of a study investigating plas-
mid DNA vaccination targeting CYP1B1 suggest that treatment
has led to improved responses to third-line therapy, but no control
group was included, nor do we find this observation convincing
when solely taking the participants with ovarian cancer into ac-
count (Gribben 2005).
Survival
Definitions of survival used in the different studies varied greatly
(Table 5 and Table 6). Furthermore, reliable statements about sur-
vival (dis)advantages can only be made based on RCTs. Only four
studies were designed to primarily evaluate survival, however, no
statistically significant differences in time to relapse and/or over-
all survival (OS) were found between participants treated with a
monoclonal antibody or placebo (Berek 2001; Berek 2004; Berek
2009; Sabbatini 2013). Many non-RCTs also evaluated survival,
frequently by comparing survival of participants with robust im-
munological responses to participants with no or weak immuno-
logical responses to treatment (Table 5 and Table 6). These results
should be interpreted with great caution as shorter survival in non-
responders could merely be a reflection of the general condition of




Monoclonal antibodies may induce anti-idiotype antibodies
(Ab2), directed primarily against the administeredmonoclonal an-
tibody, as well as anti-anti-idiotype antibodies (Ab3) directed to-
wards the target antigen. Anti-idiotype and anti-anti-idiotype an-
tibodies were evaluated in 10 out of 21 studies respectively (Table
7 and Table 8). Response percentages varied greatly (Ab2: 3% to
100%, Ab3: 0% to 100%).
Fifteen studies of other vaccine types evaluated the induction of
antigen-specific antibodies by ELISA, however only six studies
clearly definedwhen an antibody titre or concentrationwas consid-
ered positive (Table 9) (Diefenbach 2008; Galanis 2010; Kaumaya
2009; Sabbatini 2007; Sabbatini 2012; Sandmaier 1999). Large
differences in percentages of participants withmeasurable antigen-
specific antibodies (IgG: 0% to 96%) existed. Possible explana-
tions for these broad ranges are differences in 1) response defini-
tion, 2) number of treatment cycles after which humoral responses
were measured and 3) targeted antigen.
Cellular responses
The induction of T-cells against the target antigen was investi-
gated in 12 out of 21 monoclonal antibody studies (Table 10).
The presence of antigen-specific T-cells was evaluated by com-
monly used tests, such as IFN-γ ELISPOT (Ehlen 2005; Gordon
2004; Method 2002; Sabbatini 2006), proliferation assay (Ma
2002; Noujaim 2001; van Zanten-Przybysz 2002), cytokine pro-
filing (Noujaim 2001; Pfisterer 2006) and IFN-γ secretion as-
say (Ströhlein 2009). One study used the leukocyte migration
inhibition assay (Wagner 1993), which nowadays is rarely used.
Sabbatini 2013 will report the results regarding cellular responses
in a separate not yet available publication. As described above for
humoral responses, response definitions were frequently lacking
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or inadequate. Nevertheless, cellular immunity against CA-125
was reported for 21% to 80% of participants. Antibody treatment
targeting the membrane folate receptor however, did not induce
cellular responses (van Zanten-Przybysz 2002). Recognition of au-
tologous tumour cells by induced T-cells was determined in two
studies only, with positive responses in five out of eight and one out
of two participants respectively (Gordon 2004; Ströhlein 2009).
Antigen-specific cellular immune responses were evaluated for 26
out of 34 studies using other vaccine types (Table 11). The most
frequently used assay was the IFN-γ ELISPOT assay, which was
sometimes used to separately analyse CD4+ and/or CD8+ cells.
Again, response definitions for positive and/or vaccine-induced
responses were frequently absent or unclear (12 out of 34). In
four of six studies targeting NY-ESO-1, antigen-specific T-cells
were induced, with percentages of participants with NY-ESO-
1-specific CD8+ ranging from 33% to 92% (Dhodapkar 2012;
Diefenbach 2008; Nishikawa 2006; Odunsi 2007; Odunsi 2012;
Sabbatini 2012); one study did not report the results separately
for ovarian cancer participants (Dhodapkar 2012). After treat-
ment with vaccines targeting p53, p53-specific T-cells were ob-
served in 64% to 100% of participants, irrespective of type of vac-
cine (Leffers 2009a; Rahma 2012; Vermeij 2012). Lastly, studies
targeting multiple antigens demonstrated antigen-specific cellular
immunity with varying immunogenicity of the different antigens
targeted (Berinstein 2012; Brossart 2000; Chianese-Bullock 2008;
Chu 2012; Mohebtash 2011; Morse 2011; Tsuda 2004).
Secondary outcomes
Carrier-specific immunogenicity
The majority of studies using a monoclonal antibody (17 out
of 21) used a murine antibody, two studies used a trifunctional
rat-mouse hybrid (Baumann 2011; Heiss 2010), and one study
used a chimeric antibody construct (van Zanten-Przybysz 2002).
Next to antigen-specific immunity, the induction of human-anti-
mouse antibodies (HAMA) using HAMA-specific ELISA assays
was assessed in 16 studies (Table 12). HAMA were present in
4% to 97% of participants immunised (Baumann 2011; Berek
2004; Braly 2009; Ehlen 2005; Gordon 2004; Method 2002;
Möbus 2003; Pfisterer 2006; Reinartz 2004; Sabbatini 2006;
Schultes 1998). It seems that the large variation between studies
cannot be attributed to differences in dosage, but is best ascribed
to different definitions of a HAMA response i.e. some studies
only report robust responses, whereas others report all responses
above a certain threshold. Furthermore, the point in time at which
HAMA titres were measured is of importance as responses increase
in frequency and strength with repeated administrations of the
antibody (Baumann 2011; Gordon 2004; Method 2002; Möbus
2003).
Although six studies investigated synthetic carbohydrate antigens
conjugated to the keyhole limpet haemocyanin (KLH) carrier pro-
tein (Freedman 1998; MacLean 1992; MacLean 1996; Sabbatini
2000; Sandmaier 1999; Sabbatini 2007), only one study reported
on KLH-specific immunity (Sandmaier 1999). In this study, pro-
liferative responses to stimulation with KLH and the KLH-anti-
gen complex were substantially stronger than responses to the syn-
thetic carbohydrate itself in all women with ovarian cancer tested,
similar to what has previously been reported for viral vectors.
The use of recombinant viruses or bacteria as vectors was reported
by five studies (Galanis 2010; Gulley 2008; Le 2012; Mohebtash
2011;Odunsi 2012). Anti-vector immune responseswere reported
to be investigated in three of these. In a study using a recombinant
pox-virus, anti-vector immunity was induced in all participants
with ovarian cancer (Gulley 2008). A study using a recombinant
measles virus did not show any differences in anti-measles-anti-
body titres, but included participants were required to be immune
to measles virus as part of the inclusion criteria (Galanis 2010).
The use of live-attenuated listeria did result in virus-specific T-
cells in some cancer participants, however, too few participants
with ovarian cancer were tested to draw a conclusion for this spe-
cific disease entity (Le 2012).
Adverse events
For this review, adverse events were defined as any adverse change
inhealth or side effect that occurred in a personwhoparticipated in
the clinical study receiving the treatment, irrespective of whether
the event could be attributed to the treatment received.
Although 45 studies mentioned adverse events, sufficiently de-
tailed information on adverse events occurring during the study
was available for only 36 out of 55 studies. Local adverse events
were explicitly mentioned for 28 studies, all of which used local
administration of the vaccine (i.e. intradermal, intramuscular or
subcutaneous injection). When local adverse events were further
specified, these were best summarised as pain at the injection site
and local inflammatory responses (erythema, induration, pruri-
tis). Ulceration and/or abscesses at the injection site were observed
in nine of 89 participants with varying types of cancer participat-
ing in four studies (Freedman 1998; Berinstein 2012; Berinstein
2013; Gribben 2005) .
Systemic adverse events occurred in 35 studies and were explicitly
reported not to have occurred in four studies. For the remain-
ing six studies, no information on systemic adverse events could
be deduced from the manuscript. Autoimmunity was explicitly
reported by two studies. In one study, a participant with strong
immunological responses to the vaccine developed a symptomatic
hypothyroidism necessitating replacement therapy (Diefenbach
2008). A minor induction of anti-nuclear antibodies (grade I ac-
cording to Common Terminology Criteria for Adverse Events
(CTCAE) v4.0 (Trotti 2003)) was described for two participants
receiving a multi-peptide vaccine (Chianese-Bullock 2008). Aller-
gic reactions were described for a total of 14 participants (Berek
2009; Braly 2009; Ehlen 2005; MacLean 1992; Möbus 2003;
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Pfisterer 2006; Ströhlein 2009). Allergic reactions were mild and
easily managed, e.g. hypersensitivity, allergic exanthema, and ur-
ticaria. When study treatment was continued, this did not result in
renewed allergic reactions (Braly 2009; Ehlen 2005;Möbus 2003;
Pfisterer 2006).
Other systemic adverse events reported, irrespective of whether at-
tributable to the investigated drug, included haematologic changes
(e.g. anaemia, leucopenia), flu-like symptoms (including fatigue,
myalgia, arthralgia, headache, fever and chills) and gastrointesti-
nal events (e.g. nausea, vomiting, diarrhoea, and abdominal pain),
most of which were classified as grade I or II events. Serious (CTC
grade III or IV) adverse events were reported by 28 studies and
varied from recurrent or progressive disease to local ulceration at
injection site, and from abdominal pain and fever to elevated liver
enzymes. In 17 studies, no serious adverse events were reported.
Ten studies did not mention lack or presence of serious adverse
events.
D I S C U S S I O N
The aim of this review was to evaluate clinical and immunological
efficacy of antigen-specific active immunotherapy in ovarian can-
cer, whilst also obtaining an impression of safety and tolerability of
this treatment modality. The antigen-specific active immunother-
apy described in this review can largely be divided into two strate-
gies: (1) the administration of antibodies targeting a specific tu-
mour antigen and (2) the administration of, or parts of, a specific
tumour antigen itself. As expected, most studies were non-RCTs.
Antigen-specific humoral and/or cellular immunogenicity of the
different interventions showed great variation for both mono-
clonal antibody studies and studies using other strategies. This
variation may at least be partially attributed to the variation in im-
munological response definitions used by the different studies. It is
therefore not possible to reliably compare studies and infer which
intervention and/or immunisation strategy is most promising for
the induction of strong anti-tumour immunity. Furthermore, only
two studies evaluated recognition of autologous tumour cells in
vitro and none evaluated immune responses at the tumour site.
Although obtaining autologous tumour material may be burden-
some, such assays would be extremely valuable as they comprise
true interactions between induced immunity and tumour cells and
could as such provide important information on how to continue
improvement of immunotherapeutic strategies to reach clinical ef-
fectiveness.
Clinical responses to immunotherapy (i.e. tumour responses, re-
sponses to secondary treatment and survival benefits) were ob-
served only incidentally and when described reliability of results
was questionable due to the absence of clear response definitions.
Furthermore, for studies in which a monoclonal antibody target-
ing CA-125 was used, the use of CA-125 as a marker for clini-
cal response is questionable. An additional important comment
regarding the likelihood of clinical responses to immunotherapy,
especially in uncontrolled studies, which frequently include par-
ticipants with recurrent disease, is the fact that this likelihood
may be affected by the disease status at start of treatment (Leffers
2009). The indication for immunotherapeutic treatment in the
adjuvant setting is supported by the observation of enhanced anti-
gen-specific responses to immunotherapy when combined with
chemotherapeutic agents currently or previously used in the pri-
mary treatment of ovarian cancer i.e. docetaxel or cyclophospha-
mide (Garnett 2008; Laheru 2008). Four large RCTs using amon-
oclonal CA-125 antibody in the adjuvant setting after successful
primary therapy however did not demonstrate any differences in
time to relapse and/or OS between the treatment and placebo arm
(Berek 2001; Berek 2004; Berek 2009; Sabbatini 2013), which
indicates that despite immunogenicity, CA-125 targeted mono-
clonal antibody therapy is clinically ineffective. For the studies of
other vaccine types, no such conclusions can be made at this time
as large RCTs and more studies in the adjuvant, rather than recur-
rent setting have yet to be performed for the different strategies.
Adverse events, reported in sufficient detail for interpretation, were
reported in 65% of studies. A distinction was made between lo-
cal and systemic events. The latter were further subdivided in au-
toimmunity, allergy and other adverse events. We did not evaluate
whether adverse events could be or were considered attributable
to the treatment studied, although for local adverse events this
is indisputably the case. Inflammatory reactions and pain at the
injection site were frequently reported for studies using intrader-
mal, subcutaneous or intramuscular application, with ulceration
at the most severe side of the spectrum. Severe or life-threatening
systemic adverse events occurred in 62% of studies explicitly de-
scribing the occurrence or lack of severe adverse events. For mon-
oclonal antibody studies, no pattern suggestive of a underlying
treatment-associated process could be identified and events were
often considered to be associated with ovarian cancer progression.
A disturbing observation regarding adverse events is the lack of
uniformity in adverse event reporting. Reporting of safety and
tolerability of new treatment strategies should have high priority
in all studies of investigational drugs, especially in uncontrolled
phase I and II studies. To promote uniformity in adverse event
evaluation and reporting as well as the comparability of adverse
events between studies, in addition to the NCI CTCAE (Trotti
2003), theBrightonCollaboration (Brighton Collaboration 2009)
has committed itself to develop standardised, widely disseminated
and globally accepted case definitions for an exhaustive number
of adverse events following immunisation as well as guidelines for
data collection, analysis, and presentation. These case-definitions
and guidelines are freely available and we strongly recommend
that, where applicable, these are used for all immunotherapeutic
studies.
Interestingly, for 10 studies described in this review, information
11Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
from the study was collected from a meeting abstract only and
often this meeting abstract was several years old. The lack of full
text manuscripts, even after contacting abstract authors, strongly
suggests the existence of a publication bias. To avoid the disap-
pearance of negative studies, registration of trials in a prospective
trial register is widely recommended and supported by the Inter-
national Committee of Medical Journal Editors (ICMJE). How-
ever, initially in 2005 registration was only requested for RCTs.
Since July 1, 2008 all trials prospectively assigning human par-
ticipants to one or more health-related interventions to evaluate
the effects on health outcomes are required to be registered in a
clinical trial register approved by the WHO. From the ongoing
studies section it is however apparent that despite registration in a
prospective trial register, studies may suffer from publication bias
as several relatively small studies started more than five years ago
have not yet been published to date or closed according to the trial
register. In addition to registration in trial registers, the uniform
requirements for manuscripts submitted to biomedical journals
drafted by the ICMJE encourage uniformity in reporting of clin-
ical trials by stating ethical principles in conduct and reporting of
research as well as proving recommendations relating to specific
elements of editing and writing. As is obvious from this review,
the scientific community might benefit substantially if also early
phase uncontrolled clinically trials would strive for uniformity in
trial conduct and reporting.
This review also emphasises another aspect of immunotherapeutic
studies that warrants serious attention in the immunotherapeutic
scientific community i.e. the lack of consensus on 1) what assays to
use to establish immunogenicity of an intervention (Britten 2008),
2) what cut-offs to use to define true immunological responses
and 3) response definitions for clinical efficacy. Given these large
inconsistencies, it is evident that the elucidation of what type of
immunological response is necessary for and/or a surrogate marker
of clinical activity of an immunotherapeutic intervention is bur-
densome.
In summary, this review describes 55 immunotherapy studies in-
cluding 3051 women with ovarian cancer. The most striking ob-
servations of this review unfortunately do not concern the aim of
the review, but address the lack of uniformity in conduct and re-
porting of early phase immunotherapy studies. When temporar-
ily discarding this methodological heterogeneity, it seems that al-
though all strategies described are capable of inducing immunolog-
ical responses, be it humoral or cellular, clinically effectiveness has
thus far not been convincingly demonstrated. The largest body of
evidence is available for CA-125 directed antibody therapy, which
has been studied in 2339 people participating in 16 studies. As
complete or partial clinical responses were reported in only one
study and four large RCTs did not demonstrate any clinical benefit
of antibody treatment, we feel that it is unlikely that clinical ef-
fectiveness of CA-125 directed antibody therapy for ovarian can-
cer will ever be obtained. However, in view of the immunological
responses to and the usually mild side effects, we feel that fur-
ther investigation of other antigen-specific active immunotherapy
strategies in ovarian cancer is worthwhile.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At this point in time, there is no evidence of effective immunother-
apy for ovarian cancer. Although promising immunological re-
sponses have been observed for most strategies evaluated, these
do not coincide with clinical benefits for women with ovarian
cancer. Furthermore, there are currently no immunological surro-
gate markers that correlate with clinical outcomes. Until evidence
of true clinical effectiveness is available, immunotherapy should
therefore not be offered as an alternative to standard therapy for
primary or recurrent ovarian cancer.
Implications for research
Our primary recommendation relates to the necessity of unifor-
mity in trial conduct and reporting. Not until universally accepted
immunological and clinical response definitions and guidelines for
adverse events reporting are adopted in immunotherapeutic stud-
ies, will it be possible to make any inferences about the achievabil-
ity of immunotherapy as a treatment for ovarian cancer. Further-
more, expanding evaluation of immunogenicity to include recog-
nition of autologous tumour is advisable. Given the usually mild
side effects and the immunological responses witnessed in most
studies, we feel that further investigation of antigen-specific active
immunotherapy other than CA-125 targeted antibody therapy in
ovarian cancer in randomised controlled trials is worthwhile.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baumann 2011
Methods Randomised controlled phase II trial
Participants 45 ovarian cancer patients with evidence of disease after first- or second-line chemother-
apy
Interventions Intraperitoneal trifunctional bispecific antibody (catumaxomab - EpCAM): low dose
(10-10-10-10 µg) versus high dose (10-20-50-100 µg)
Outcomes Tumour responses
Survival (progression free survival/overall survival)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Unclear risk Not explicitly stipulated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient data to permit judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar reasons for missing data across groups
Selective reporting (reporting bias) Unclear risk Study protocol not publicly available
Other bias Low risk
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Berek 2001
Methods Randomised placebo-controlled trial
Participants 252 stage III/IV ovarian cancer patients after successful primary surgery and chemother-
apy
Interventions Intravenous monoclonal antibody (oregovomab - CA125) versus placebo
Outcomes Survival (time to relapse)
Immune responses: humoral (Ab2, HAMA)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the sequence
generation process to permit judgement of ‘Low
risk’ or ‘High risk’, only abstract available
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judgement of
‘Low risk’ or ‘High risk’, only abstract available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judgement of
‘Low risk’ or ‘High risk’, only abstract available
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement of
‘Low risk’ or ‘High risk’, only abstract available
Other bias High risk Possible publication bias
Berek 2004
Methods Randomised placebo-controlled phase II Trial
Participants 145 stage III/IV ovarian cancer patients with complete clinical response to primary
therapy
Interventions Intravenous monoclonal antibody (oregovomab) versus placebo
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Berek 2004 (Continued)
Outcomes Survival (time to relapse/overall survival)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the se-
quence generation process to permit judge-
ment of ‘Low risk’ or ‘High risk’
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Other bias Low risk
Berek 2009
Methods Randomised placebo-controlled phase III trial
Participants 371 stage III/IV ovarian cancer patients with complete clinical response to primary
therapy
Interventions Intravenous monoclonal antibody (oregovomab) versus placebo
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Berek 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised randomisation procedure
Allocation concealment (selection bias) Low risk Centralised randomisation procedure
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded to treatment assignment, post-ran-
domisation immune responses and CA125
measurements
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to treatment assignment, post-ran-
domisation immune responses and CA125
measurements
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Other bias Low risk
Berinstein 2012
Methods Uncontrolled phase I study
Participants 23 late stage cancer HLA-A2+ participants with complete or partial response to primary
therapy (ovarian cancer n = 6)
Interventions Subcutaneous 7 short peptides (topoisomerase IIα, integrin β8 subunit precursor, ABI-
binding protein C3, TACE/ADAM17, junction plakglobin, EDDR1, BAP31)
Adjuvant: DepoVax





Bias Authors’ judgement Support for judgement
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Berinstein 2012 (Continued)
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Berinstein 2013
Methods Uncontrolled phase I study
Participants 19 women with ovarian cancer with unknown disease status
Interventions Subcutaneous peptides (survivin)
Adjuvant: DepoVax




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Braly 2009
Methods Randomised controlled phase II Trial
Participants 40 stage III/IV ovarian cancer patients after primary debulking surgery with or without
residual disease
Interventions Intravenous monoclonal antibody (oregovomab - CA125): concurrent (SIM) or delayed
(OWD) with standard carboplatin/paclitaxel primary chemotherapy
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Braly 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding or incomplete blinding, but the
review authors judge that the outcome is not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers
across intervention groups, with similar reasons
for missing data across groups
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’
Other bias Low risk
Brossart 2000
Methods Uncontrolled phase I/II study
Participants 10 participants with measurable residual or recurrent breast or ovarian cancer (3 women
with ovarian cancer)






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Chianese-Bullock 2008
Methods Uncontrolled phase I study
Participants 9 women with ovarian cancer with or without residual or recurrent disease after primary
therapy
Interventions Subcutaneous & intradermal multi peptide vaccine (FBP, Her-2/Neu & MAGE-A1)






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Chu 2012
Methods Randomised controlled phase I/II study
Participants 14ovarian cancer patientswith complete clinical response to primary therapy (10 received
treatment so far)
Interventions Intradermal peptide pulsed Dendritic Cells (Her-2/Neu, hTERT, PADRE): vaccine






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the sequence
generation process to permit judgement of
‘Low risk’ or ‘High risk’
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Chu 2012 (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding or incomplete blinding, but the
review authors judge that the outcome is not
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers
across intervention groups, with similar rea-
sons for missing data across groups
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Other bias High risk Early termination due to financial limita-
tions.
Dhodapkar 2012
Methods Uncontrolled phase I study
Participants 45 participants with advanced malignancies, exact disease status unknown (ovarian can-
cer n = 6)
Interventions Fusion protein of full length tumour antigen and human monoclonal antibody specific
for DEC-205
Adjuvants: TLR agonist resiquimod and/or Poly-ICLC




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Diefenbach 2008
Methods Uncontrolled phase I study
Participants 9 participants with ovarian cancer with complete clinical response to primary therapy
Interventions Subcutaneous short peptide (NY-ESO-1)
Adjuvant: Montanide ISA-51
Outcomes Survival (time to progression)
Tumour responses




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Ehlen 2005
Methods Uncontrolled phase II study
Participants 13 women with ovarian cancer with measurable recurrent disease
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (time to progression/survival)
Tumour responses




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Freedman 1998
Methods Randomised controlled phase II study
Participants 30 ovarian cancer patients previously treatedwith platinum-based chemotherapy (disease
status at study entry not described)
Interventions Subcutaneous KLH conjugate (Sialyl-Tn) at two different dosages
Adjuvant: detox B





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the sequence
generation process to permit judgement of
‘Low risk’ or ‘High risk’, only abstract available
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’, only abstract avail-
able
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’, only abstract avail-
able
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclusions to
permit judgement of ‘Low risk’ or ‘High risk’,
only abstract available
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’, only abstract avail-
able
Other bias High risk Possible publication bias
31Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Galanis 2010
Methods Uncontrolled phase I study
Participants 21 ovarian cancer patients with persistent, recurrent or progressive disease after primary
therapy






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Goh 2013
Methods Randomised controlled phase IIb trial
Participants 63 patients in complete remission after primary therapy






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the sequence
generation process to permit judgement of
‘Low risk’ or ‘High risk’, only abstract available
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’, only abstract avail-
able
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Goh 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’, only abstract avail-
able
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’, only abstract avail-
able
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclusions to
permit judgement of ‘Low risk’ or ‘High risk’,
only abstract available
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’, only abstract avail-
able
Other bias Unclear risk Insufficient information to permit judgement
of ‘Low risk’ or ‘High risk’, only abstract avail-
able; study recently completed
Gordon 2004
Methods Uncontrolled phase II study
Participants 20 ovarian cancer patients with recurrent disease
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (time to progression/survival)
Tumour responses




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Gribben 2005
Methods Uncontrolled phase I study
Participants 17 participants with advanced cancer with progressive disease (ovarian cancer n = 6)






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Gulley 2008
Methods Uncontrolled phase I/II study
Participants 25 participants with CEA or MUC1 over-expressing metastatic cancer with progressive
disease following standard chemotherapy (ovarian cancer n = 3)
Interventions Subcutaneous recombinant pox virus (CEA, MUC1): 1x vaccinia, ≥ 4 fowlpox
Adjuvant: local GM-CSF
Outcomes Survival (progression free survival/overall survival)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Heiss 2010
Methods Randomised controlled open-label phase II/III trial
Participants 258 patients with malignant ascites due to epithelial cancer (ovarian cancer n = 129)
Interventions Intraperitoneal trifunctional antibody (EpCAM) + paracentesis versus paracentesis





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the se-
quence generation process to permit judge-
ment of ‘Low risk’ or ‘High risk’
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding or incomplete blinding, but
the review authors judge that the outcome
is not likely to be influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Incomplete outcome data (attrition bias)
All outcomes
High risk Reason for missing outcome data likely to
be related to true outcome, with either im-
balance in numbers or reasons for missing
data across intervention groups
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Other bias Low risk
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Imhof 2013
Methods Uncontrolled phase I study
Participants 15 participants with complete remission after primary therapy
Interventions Intradermal dendritic cells pulsed with mRNA (TERT) and short peptide (Survivin)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Kaumaya 2009
Methods Uncontrolled phase I study
Participants 24 participants with metastatic and/or recurrent solid tumours (ovarian cancer n = 5)







Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Le 2012
Methods Uncontrolled phase I study
Participants 17 participants with advanced cancers after prior therapy (ovarian cancer n = 2)
Interventions Intravenous recombinant listeria (mesothelin)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Leffers 2009a
Methods Uncontrolled phase II study
Participants 20 women with epithelial ovarian cancer with (biochemical) recurrence not (yet) eligible
for renewed chemotherapy
Interventions Subcutaneous synthetic long peptides (p53)
Adjuvant: Montanide ISA51
Outcomes Survival (disease specific survival)
Tumour responses




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Letsch 2011
Methods Uncontrolled study
Participants 18 participants with WT1 expressing solid tumours (disease status unreported) (ovarian
cancer n = 8)







Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Ma 2002
Methods Uncontrolled study
Participants 4 women with ovarian cancer (disease status at study entry not described)
Interventions Monoclonal antibody (MJ01- CA125)
Outcomes Immune response: cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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MacLean 1992
Methods Uncontrolled phase I study
Participants 10 women with ovarian cancer and residual or recurrent disease







Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
MacLean 1996
Methods Uncontrolled phase II study
Participants 34 women with ovarian cancer and evaluable residual or recurrent disease
Interventions Subcutaneous KLH conjugate (Sialyl-Tn)
Adjuvant: detox B




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Method 2002
Methods Randomised controlled Study
Participants 102 women with ovarian cancer after primary therapy (disease status at study entry not
described)
Interventions Intravenous monoclonal antibody (oregovomab - CA125): 2 gifts versus 3 gifts, versus
6 gifts
Outcomes Tumour responses




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the sequence generation
process to permit judgement of ‘Low risk’ or ‘High risk’,
only abstract available
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judgement of ‘Low
risk’ or ‘High risk’, only abstract available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding or incomplete blinding, but the review au-
thors judge that the outcome is not likely to be influ-
enced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judgement of ‘Low
risk’ or ‘High risk’, only abstract available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclusions to permit
judgement of ‘Low risk’ or ‘High risk’, only abstract
available
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement of ‘Low
risk’ or ‘High risk’, only abstract available
Other bias Unclear risk Insufficient information to permit judgement of ‘Low
risk’ or ‘High risk’, only abstract available
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Mohebtash 2011
Methods Uncontrolled study
Participants 31 metastatic ovarian and breast cancer patients (ovarian cancer n = 14)
Interventions Subcutaneous recombinant pox virus (MUC1 and CEA)
Adjuvant: local GM-CSF
Outcomes Survival: median time to progression 2 months (range 1-36)
Immune responses (cellular)
Adverse events: no severe adverse events, mostly locoregional grade 1 or 2 reactions
Notes max. 3 patients overlap with Gulley 2008
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Morse 2011
Methods Uncontrolled phase I study
Participants 15 ovarian and breast cancer patients with no evidence of disease after prior therapy
(ovarian cancer n = 8)
Interventions Intradermal and subcutaneous short peptides in two groups (Group 1: APC, HHR6A,
BAP31, replication protein A, Abl-binding protein 3c, cyclin I; Group 2: topoisomerase
IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g-catenin, EEDDR1)






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Möbus 2003
Methods Retrospective uncontrolled study
Participants 44 ovarian cancer patients with clinical recurrence after primary therapy
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (time first dose to death/overall survival)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Nicholson 2004
Methods Uncontrolled phase I study
Participants 26 epithelial ovarian cancer patients with residual disease (n = 19), microscopic disease
(n = 3) after chemotherapy or 2nd complete remission (n = 4)
Interventions Monoclonal antibody (HMFG1 -Muc1); first gift intraperitoneal (n = 16) or intravenous
(n = 10), then id boosts
Adjuvant: aluminium hydroxide
Outcomes Tumour responses




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Nishikawa 2006
Methods Uncontrolled phase II study
Participants 4 epithelial ovarian cancer patients after primary debulking surgery (disease status at
study entry not described)
Interventions Short peptide (NY-ESO-1)
Adjuvant: incomplete Freund’s adjuvant
Outcomes Immune responses: cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Noujaim 2001
Methods Retrospective uncontrolled study
Participants 184 ovarian cancer patients with clinically or radiologically suspected recurrence
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (overall survival)
Immune responses: humoral (Ab3), cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Odunsi 2007
Methods Uncontrolled phase I study
Participants 18 ovarian cancer patients after chemotherapy for primary or recurrent disease with or
without residual disease
Interventions Subcutaneous short peptide (NY-ESO-1)
Adjuvant: incomplete Freund’s adjuvant
Outcomes Survival: median time to progression 19.0 months
Tumour responses: 1x CR, 17x unknown
Immune responses: humoral, cellular
Adverse events: well-tolerated, no further description
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Odunsi 2012
Methods Uncontrolled phase I/II study
Participants 22 women with ovarian cancer without evidence of disease after primary therapy
Interventions intradermal recombinant virus (NY-ESO-1); 1x vaccinia virus, 6x fowlpox boost
Outcomes Survival (disease free survival)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Ohno 2009
Methods Uncontrolled phase II study
Participants 12patientswith gynaecologicalmalignancies resistant to standard therapy (ovarian cancer
n = 6)





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Peethambaram 2009
Methods Uncontrolled phase I study
Participants 18 patients with refractory metastatic tumours (ovarian cancer n = 4)
Interventions Intravenous recombinant fusion antigen pulsed antigen presenting cells (Her-2/neu)
Adjuvant: GM-CSF (included in the recombinant fusion product)






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Pfisterer 2006
Methods Uncontrolled phase I study
Participants 36 Stage I-IV ovarian cancer patients within 6 weeks after completion of chemotherapy
for recurrent disease (disease status at study entry not described)
Interventions Subcutaneous monoclonal antibody (abagovomab - CA125)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Rahma 2012
Methods Uncontrolled phase II study
Participants 21 ovarian cancer patients without evidence of disease after prior therapy
Interventions Subcutaneous short peptide (p53) versus intravenous peptide-pulsed dendritic cells (p53)
Adjuvant: Montanide ISA-51 and GM-CSF (only in cohort-treated with peptide)






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Reinartz 2004
Methods Uncontrolled multicentre phase Ib/II study
Participants 119 patients with ovarian cancer after at least primary treatment (disease status at entry
not described)
Interventions Intramuscular monoclonal antibody (ACA125 - CA125)





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Sabbatini 2000
Methods Uncontrolled phase I study
Participants 25 ovarian cancer patients with complete clinical response to chemotherapy after residual
or recurrent disease following primary therapy
Interventions Subcutaneous KLH conjugate (LewisY penta saccharide - MUC-1)
Adjuvant: QS-21





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
47Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sabbatini 2006
Methods Randomised, open-label multicentre phase I study
Participants 42 stage II-IV ovarian cancer patients after chemotherapy for recurrence of disease with
complete clinical response or measurable disease (< 2 cm)
Interventions Intramuscular (im) or subcutaneous (sc) monoclonal antibody (abagovomab - CA125):
4 cohorts (2x im; 2x sc; 0.2 mg or 2 mg)
Outcomes Survival (time to progression)
Tumour responses




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Standard 2x2 factorial design
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding or incomplete blinding, but
the review authors judge that the outcome
is not likely to be influenced by lack of
blinding;
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement of ‘Low risk’ or
‘High risk’
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’
Other bias Low risk
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Sabbatini 2007
Methods Uncontrolled phase I/II study
Participants 11 epithelial ovarian cancer patients with complete clinical remission after primary ther-
apy or chemotherapy for recurrent disease
Interventions Subcutaneous heptavalent KLH conjugate (GM2, Globo-H, Lewis Y, Tn-MUC1, Tn
(c) sTN(c), TF(c))




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Sabbatini 2012
Methods Uncontrolled phase I study
Participants 28 ovarian cancer patients in second or third remission
Interventions Subcutaneous overlapping long peptides (NY-ESO-1)
Adjuvant: cohort 1 - no (n = 4); cohort 2: Montanide ISA-51 (n = 13); cohort 3: poly-
ICLC in Montanide ISA-51 (n = 11)
Outcomes Survival (time to progression)
Tumour responses




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Sabbatini 2013
Methods Randomised placebo-controlled trial
Participants 888 ovarian cancer patients in complete clinical remission after primary therapy
Interventions Subcutaneous monoclonal antibody (abagovomab - CA125)
Outcomes Survival (recurrence free survival, overall survival)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised randomisation
Allocation concealment (selection bias) Low risk Centralised randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and key study personnel
ensured, and unlikely that the blinding could
have been broken
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessment ensured, and
unlikely that the blinding could have been bro-
ken
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers
across intervention groups, with similar reasons
for missing data across groups
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement of
‘Low risk’ or ‘High risk’
Other bias Low risk
Sandmaier 1999
Methods Uncontrolled phase II study
Participants 40 breast or ovarian cancer (n = 7) patients who underwent high-dose chemotherapy
and autologous or syngeic stem cell rescue (disease status at study entry unknown)
Interventions Subcutaneous KLH conjugate (Sialyl-Tn)
Adjuvant: detox B
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Sandmaier 1999 (Continued)
Outcomes Immune responses: humoral, cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Schultes 1998
Methods Retrospective uncontrolled study
Participants 75 stage I-IV ovarian cancer patients (disease status at study entry not described)
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (overall survival)
Immune responses: humoral (Ab2, Ab3, HAMA)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Ströhlein 2009
Methods Uncontrolled phase I study
Participants 9 patients with progressive peritoneal carcinomatosis (ovarian cancer n = 2)
Interventions Intraperitoneal trifunctional antibody targeting EpCAM (n = 1) or Her2/Neu (n = 1)
Outcomes Survival: not reported separately for ovarian cancer patients
Tumour responses
Immune responses: cellular, humoral (HAMA)
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Takeuchi 2013
Methods Uncontrolled phase I/II study
Participants 38 ovarian cancer patients with advanced/recurrent disease
Interventions Subcutaneous peptide cocktail (HLA-A24 - n = 23: FOXM1,MELK,HJURP,VEGFR1,




Immune responses (not adequately reported)
Adverse events (not adequately reported)
Notes meeting abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Tsuda 2004
Methods Uncontrolled phase I/II study
Participants 14 patients with gynaecological cancer after primary therapy (ovarian cancer n = 5; NED
n = 2)
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Tsuda 2004 (Continued)
Interventions Subcutaneous individualised short peptide cocktail
Adjuvant: Montanide ISA-51
Outcomes Tumour responses
Immune responses: humoral, cellular
Adverse events: not separately described for ovarian cancer patients
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
van Zanten-Przybysz 2002
Methods Uncontrolled phase I/II study
Participants 5 patients with residual or recurrent ovarian cancer after primary debulking surgery and
at least one course of chemotherapy
Interventions Intravenous monoclonal antibody (c-MOv18 - membrane folate receptor)
Outcomes Survival: median time first dose to death 22.0 months
Tumour responses: 3x PD, 2x SD
Immune responses: cellular
Adverse events: max. grade I events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
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Vermeij 2012
Methods Uncontrolled phase II study
Participants 12 women with epithelial ovarian cancer with (biochemical) recurrence not (yet) eligible
for renewed chemotherapy
Interventions Subcutaneous synthetic long peptides (p53)
Adjuvant: Montanide ISA51






Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Wagner 1993
Methods Retrospective uncontrolled study
Participants 58 patients with advanced stage ovarian cancer after primary treatment with high pre-
operative CA-125 levels (disease status at study entry not described)




Immune responses: humoral (Ab2), cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Uncontrolled trial
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Wagner 1993 (Continued)
Allocation concealment (selection bias) High risk Uncontrolled trial
GM-CSF: Granulocyte-macrophage colony-stimulating factor
HAMA: human-anti-mouse antibodies
KLH: keyhole limpet haemocyanin
NED: no evidence of disease
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 2000 Only one woman with EOC, no ASAI
Bender 2007 Only one woman with EOC
Bernal 2012 Only one woman with EOC, no ASAI
Carbone 2005 Only one woman with EOC
Disis 1999 Impossible to distinguish between other and women with ovarian cancer
Disis 2000 Impossible to distinguish between other and women with ovarian cancer
Disis 2002 Impossible to distinguish between other and women with ovarian cancer
Disis 2002a Only one woman with EOC
Disis 2004 Impossible to distinguish between other and women with ovarian cancer
Disis 2004a Only one woman with EOC
Galanis 2013 No ASAI
Haakenstad 2012 Impossible to distinguish between other and women with ovarian cancer
Hasumi 2011 No ASAI
Hernando 2002 Autologous tumour lysate vaccine
Hernando 2007 Only one woman with EOC
Holmberg 2000 Impossible to distinguish between breast & women with ovarian cancer participants
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(Continued)
Hui 1997 No ASAI
Jager 2006 Only one woman with EOC
Kandalaft 2010 Autologous tumour lysate vaccine
Karbach 2010 Only one woman with EOC
Kato 2010 Impossible to distinguish between other and women with ovarian cancer
Khranovska 2011 Autologous tumour lysate vaccine
Knutson 2001 Only one woman with EOC
Knutson 2002 Women with EOC withdrew before evaluation of immune responses
Letsch 2008 Impossible to distinguish between other and women with ovarian cancer
Loveland 2006 Only one woman with EOC
Manjunath 2012 Only one woman with EOC
Marshall 2005 Only one woman with ovarian cancer
Miotti 1999 Autologous T-cell vaccine
Morse 1999 Impossible to distinguish between other and women with ovarian cancer
Morse 2003 Uncertain if and how many women with ovarian cancer were included
Morse 2011a Impossible to distinguish between other and women with ovarian cancer; unclear number of women with ovarian
cancer
Murray 2002 Only one woman with EOC
Parkhurst 2004 No women with EOC
Reddish 1996 Impossible to distinguish between other and women with ovarian cancer
Salazar 2006 Impossible to distinguish between other and women with ovarian cancer
Schiffman 2002 No immunisations carries out
Yacyshyn 1995 Additional results to MacLean 1992; irrelevant for review
Zaks 1998 Impossible to distinguish between other and women with ovarian cancer
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ASAI: antigen-specific active immunotherapy
EOC: epithelial ovarian cancer
Characteristics of ongoing studies [ordered by study ID]
NCT00003002
Trial name or title Her-2/neu vaccine plus GM-CSF in treating participants with stage III or stage IV breast, ovarian, or non-
small cell lung cancer
Methods Uncontrolled phase I
Participants Participants with stage III or IV HER-2/neu expressing breast, ovarian, or non-small cell lung cancer
Interventions Intradermal vaccinations of HER-2/neu derived peptides with sargramostim (GM-CSF)
Outcomes Immune responses
Adverse events
Starting date April 1996
Contact information
Notes Completed January 2004, no publication available
NCT00004604
Trial name or title Biological therapy in treating patients with metastatic cancer
Methods Uncontrolled phase I
Participants 24participantswith histologically confirmedmetastatic adenocarcinoma expressing carcinoembryonic antigen
(CEA) that has failed conventional therapy
Interventions Intravenous CEA RNA-pulsed autologous DC
Outcomes Adverse events
Immune responses
Clinical and biochemical response
Starting date February 1998
Contact information
Notes Completed July 2002, no publication available
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NCT00006041
Trial name or title Vaccine therapy in treating patients with ovarian, fallopian tube, or peritoneal cancer
Methods Uncontrolled phase I
Participants 18 participants with histologically confirmed ovarian, fallopian tube, or peritoneal epithelial cancer (any stage
at diagnosis). Refractory or recurrent after cytoreductive surgery and at least one prior regimen of platinum
based chemotherapy
Interventions Glycosylated MUC-1-KLH vaccine plus QS21
Outcomes Adverse events
Immune responses
Starting date February 2000
Contact information
Notes Completed February 2002, no publication available
NCT00091000
Trial name or title An open label pilot study to evaluate the safety and tolerability of PANVAC-V (Vaccinia) and PANVAC-F
(Fowlpox) in combination with sargramostim in adults with metastatic carcinoma
Methods Phase II
Participants 51 participants with histologically confirmed colorectal, non-colorectal, ovarian, or breast carcinoma with
evidence of disease






Starting date July 2004
Contact information
Notes
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NCT00373217
Trial name or title Evaluation of the immunogenicity of vaccinationwith synthetic peptides in adjuvant in patients with advanced
ovarian, primary peritoneal, or fallopian tube cancer
Methods Phase II study
Participants 28 primary stage III/IV women with ovarian cancer
Interventions Neoadjuvant paclitaxel/carboplatin followed by surgical debulking, vaccine therapy*, adjuvant paclitaxel/
carboplatin or, surgical debulking, vaccine therapy*, followed by adjuvant paclitaxel/carboplatin *id & sc
synthetic peptides, (MAGE-A1:161-169, FBP:1901-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-
2/neu:754-762) and tetanus toxoid helper peptide adjuvant: Montanide ISA-51
Outcomes Immune responses




Trial name or title A phase 1 open-label study of the safety and feasibility of ZYC300 administration with cyclophosphamide
pre-dosing
Methods Phase I
Participants 22 advanced stage malignancies with evidence of disease and no therapeutic options





Starting date November 2006
Contact information
Notes Study completion January 2009. No published records available
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NCT00803569
Trial name or title Phase I study of ALVAC(2)-NY-ESO-1(M)/TRICOM in patients with epithelial ovarian, fallopian tube or
primary peritoneal carcinoma whose tumors express NY-ESO-1 or LAGE-1 antigen
Methods Phase I
Participants 12 stage II-IV women with ovarian cancer with complete response to primary or secondary (chemo)therapy








Trial name or title A phase III randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933) + OPT-
821 Versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second
or third complete remission
Methods Randomised phase III study
Participants 164 stage II-IV woman with ovarian cancer in second or third clinical remission





Starting date January 2009
Contact information
Notes Possibly same study as NCT00693342
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NCT00887016
Trial name or title Open label phase I study to evaluate the safety and tolerability of vaccine (GI-6207) consisting of whole,
heat-killed recombinant saccharomyces cerevisiae genetically modified to express CEA protein in adults with
metastatic CEA-expressing carcinoma
Methods Phase I study
Participants 28 CEA-overexpressing cancer participants without therapeutic options









Trial name or title A phase I clinical trial of NY-ESO-1 protein immunization in combination with 5-AZA-2’-deoxycytidine
(decitabine) in patients receiving liposomal doxorubicin for recurrent epithelial ovarian or primary peritoneal
carcinoma
Methods Phase I
Participants 18 women with ovarian cancer with recurrent disease
Interventions Decitabine in combination with NY-ESO-1 peptide vaccine (emulsified with incomplete Freund’s adjuvant




Starting date April 2009
Contact information
Notes
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NCT00948961
Trial name or title A study of CDX-1401 in patients with malignancies known to express NY-ESO-1
Methods Uncontrolled phase I/II dose escalation
Participants 70 participants with a NY-ESO-1 expressing cancer type with progression after prior therapies with curative
potential or approved salvage therapies




Starting date September 2009
Contact information
Notes Completed February 2014
NCT01223235
Trial name or title Polyvalent vaccine-KLH conjugate + Opt-821 given in combination with bevacizumab
Methods Uncontrolled phase I
Participants 22 participants who have recently completed chemotherapy and/or surgery for recurrent disease epithelial
carcinoma arising from the ovary, fallopian tube or peritoneum








Trial name or title Unimolecular pentavalent (GloboH-GM2-sTn-TF-Tn) immunization of patients with epithelial ovarian,
fallopian, tube, or peritoneal cancer in first remission
Methods Uncontrolled phase I
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NCT01248273 (Continued)
Participants 24 participants in first complete remission after cytoreductive surgery and platinum-based chemotherapy for
epithelial carcinoma arising in the ovary, fallopian tube or peritoneum








Trial name or title Vaccine therapy in treating patients with stage III-IV or recurrent ovarian cancer
Methods Uncontrolled phase I
Participants 22 participants with advanced stage or recurrent ovarian cancer treated to complete remission with standard
therapies








Trial name or title Trial of vaccine therapy in recurrent platinum sensitive ovarian cancer patients
Methods Uncontrolled phase I/II
Participants 20 women with epithelial ovarian cancer with relapse and platinum-sensitive cancer responding to chemo-
therapy
Interventions Intradermal immunization with dendritic cells loaded with amplified ovarian cancer stem cellmRNA, hTERT
and Survivin
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Trial name or title Vaccine therapy in treating patients with metastatic solid tumours
Methods Uncontrolled phase I
Participants 36 participants with an incurable metastatic solid tumour









Trial name or title Vaccine therapy with or without sirolimus in treating patients with NY-ESO-1 expressing solid tumours
Methods Uncontrolled phase 1
Participants 30 participants with solid NY-ESO-1 or LAGE-1 expressing tumours at high risk of recurrence or with
minimal residual disease
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NCT01522820 (Continued)




Trial name or title Sirolimus and vaccine therapy in treating patients with stage II-IV ovarian epithelial, fallopian tube, or primary
peritoneal cavity cancer
Methods Uncontrolled phase I
Participants 12 women with completed therapy for primary or recurrent disease with asymptomatic residual disease or
complete remission









Trial name or title Phase I/IIa trial of folate binding protein vaccine in ovarian cancer
Methods Uncontrolled phase I/IIa
Participants 60 women with ovarian, endometrial, fallopian and peritoneal cancer after completion of first line therapy
with no evidence of disease at inclusion
Interventions Intradermal injection with E39 peptide / GM-CSF vaccine
Outcomes Adverse events
Survival
Starting date April 2012
Contact information
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Trial name or title Clinical trial of therapeutic vaccine with NY-ESO-1 in combination with the adjuvant monophosphoryl lipid
A (MPLA)
Methods Uncontrolled phase I/II
Participants 15 participants with a NY-ESO-1 expressing malignancy after standard treatment
Interventions Intramuscular injection with NY-ESO-1 combined with MPLA vaccine
Outcomes Adverse events
Immune responses




Trial name or title Cyclophosphamide and vaccine therapy in treating patients with stage II-III breast, ovarian, primary peri-
toneal, or fallopian tube cancer
Methods Uncontrolled phase I
Participants 24 women in complete remission after systemic treatment of breast, ovarian, primary peritoneal of fallopian
tube cancer
Interventions Oral cyclophosphamide and intradermal multi-epitope folate receptor alpha peptide vaccine
Outcomes Adverse events
Immune responses
Starting date July 2012
Contact information
Notes
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NCT01616303
Trial name or title A controlled study of effectiveness of oregovomab (antibody) plus chemotherapy in advanced ovarian cancer
Methods Randomised open label phase II
Participants 80 women with newly diagnosed ovarian, tubal or peritoneal cancer after optimal cytoreductive surgery about
to start first-line chemotherapy









Trial name or title Clinical study of WT2725 in patients with advanced solid malignancies
Methods Uncontrolled phase I








Trial name or title Chemo-immunotherapy (gemcitabine, interferon-alpha and p53 SLP) in patients with platinum resistant
ovarian cancer (CHIP)
Methods Non-randomised study
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NCT01639885 (Continued)
Participants 15 women with recurrent ovarian cancer, peritoneal cavity or fallopian tube cancer overexpressing p53 with
disease progression or relapse after previous platinum-based therapy
Interventions Standard care (gemcitabine) vs gemcitabine combined with interferon-alpha 2b vs gemcitabine combined









Trial name or title Decitabine, vaccine therapy, and pegylated liposomal doxorubicin hydrochloride in treating patients with
recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer
Methods Uncontrolled phase I
Participants 18 women with relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer who are to receive
liposomal doxorubicin as salvage therapy for recurrent disease
Interventions intravenous decitabine, intravenous liposomal doxorubicin, subcutaneous NY-ESO-1 peptide vaccine in




Starting date April 2009
Contact information
Notes study completed June 2013, no publication available
GM-CSF: Granulocyte-macrophage colony-stimulating factor
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S






Sample Definition and Selection
Are the inclusion and exclusion criteria clearly defined?
Is the study population a representative selection of the true
population?








Are the interventions clearly defined (type of vaccine, anti-
gen, adjuvant, route of vaccination and vaccination sched-
ule)?









Are the selected outcome measures clearly specified?
Are the outcome measures relevant?









Is there an adequate rationale for the number of patients
included?
Is there an adequate description of withdrawal / exclusion
of patients during the study?




Table 2. Overview of included studies
Study Design N Disease status Target antigen Type of intervention
Baumann 2011 RCT 45 ED after first- and/or sec-
ond line chemotherapy
EpCAM antibody (low dose vs
high dose)
Berek 2001 RCT 252 NED
after primary surgery and
chemotherapy
CA-125 antibody versus placebo
Berek 2004 RCT 145 NED
after primary surgery and
chemotherapy
CA-125 antibody versus placebo
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Table 2. Overview of included studies (Continued)
Berek 2009 RCT 317 NED
after primary surgery and
chemotherapy
CA-125 antibody versus placebo
Berinstein 2012 uncontrolled phase
I
6 NED or ED after pri-
mary surgery
topoisomerase IIα, Inte-
grin β8 subunit precur-





Berinstein 2013 uncontrolled phase
I
19 unknown survivin short peptides
Braly 2009 RCT 40 NED or ED after pri-
mary surgery
CA-125 antibody (concurrent or
delayed with standard
chemotherapy)
Brossart 2000 uncontrolled phase
I/II
3 residual or recurrent dis-
ease











Chu 2012 RCT 11 NED after primary ther-





cells (with versus without
cyclophosphamide)
Dhodapkar 2012 uncontrolled phase
I
6 unknown NY-ESO-1 fusion protein
Diefenbach 2008 uncontrolled phase
I
9 NED
after primary surgery and
chemotherapy
NY-ESO-1 short peptide
Ehlen 2005 uncontrolled phase
II
13 measurable recurrent dis-
ease
CA-125 antibody
Freedman 1998 RCT 30 unknown Sialyl-Tn KLH conjugate (low dose
versus high dose)
Galanis 2010 uncontrolled phase
I




Goh 2013 RCT 63 NED after first- or sec-
ond line therapy
MUC1 protein-pulsed dendritic
cells versus standard of
care
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Table 2. Overview of included studies (Continued)
Gordon 2004 uncontrolled phase
II
20 recurrent disease CA-125 antibody
Gribben 2005 uncontrolled phase
I
6 ED CYP1B1 plasmid DNA
Gulley 2008 uncontrolled phase
I/II
3 progressive disease after
standard chemotherapy
CEA, MUC1 recombinant virus
Heiss 2010 RCT 129 recurrent malignant as-
cites
EpCAM antibody +paracentesis vs
paracentesis
Imhof 2013 uncontrolled phase
I
15 NED after primary ther-
apy
TERT, survivin mRNA- and peptide-
pulsed dendritic cells
Kaumaya 2009 uncontrolled phase
I
5 ED after prior therapy Her2/neu long peptides
Le 2012 uncontrolled phase
I
2 ED after prior therapy mesothelin recombinant bacteria
Leffers 2009a uncontrolled phase
II
20 recurrent disease p53 long peptides
Letsch 2011 uncontrolled 8 unknown WT1 short peptide
Ma 2002 uncontrolled 4 unknown CA-125 antibody
MacLean 1992 uncontrolled phase
I
10 residual or recurrent dis-
ease
Thomson Friedenreich KLH conjugate
MacLean 1996 uncontrolled phase
II
34 residual or recurrent dis-
ease
Sialyl-Tn KLH conjugate
Method 2002 RCT 102 unknown CA-125 antibody (2 vs 3 vs 6 gifts)
Möbus 2003 retrospective
uncontrolled
44 recurrent disease after pri-
mary therapy
CA-125 antibody
Mohebtash 2011 uncontrolled 14 recurrent or residual dis-
ease after therapy
CEA, MUC1 recombinant virus
Morse 2011 uncontrolled phase
I




tion protein A, Abl-bind-
ing protein 3c, cyclin I,
topoisomerase IIα/β, in-
tegrin β 8 subunit pre-
short peptides
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Table 2. Overview of included studies (Continued)
cursor, CDC2, TACE, g-
catenin, EEDDR1
Nicholson 2004 uncontrolled phase
I
26 residual disease after pri-
mary therapy or 2nd
complete remission
MUC1 antibody
Nishikawa 2006 uncontrolled phase
II
4 unknown NY-ESO-1 short peptide
Noujaim 2001 retrospective
uncontrolled
184 recurrent disease CA-125 antibody
Odunsi 2007 uncontrolled phase
I
18 NED or ED after chemo-
therapy for primary or re-
current disease
NY-ESO-1 short peptide
Odunsi 2012 uncontrolled phase
I/II
22 NED after primary ther-
apy
NY-ESO-1 recombinant virus
Ohno 2009 uncontrolled phase
II





4 progressive disease after
therapy
Her-2/neu fusion protein pulsed
antigen presenting cells
Pfisterer 2006 uncontrolled phase
I
36 unknown CA-125 antibody
Rahma 2012 uncontrolled phase
II
21 NED p53 short peptide versus pep-
tide-pulsed dendritic cells
Reinartz 2004 uncontrolled phase
Ib/II
119 unknown CA-125 antibody
Sabbatini 2000 uncontrolled phase
I
25 NED after chemotherapy
for primary or recurrent
disease
MUC1 KLH conjugate
Sabbatini 2006 RCT 42 NED or ED (<2cm) af-




Sabbatini 2007 uncontrolled phase
I/II
11 NED after chemotherapy







Sabbatini 2012 uncontrolled phase
I
28 NED after second- or
third line therapy
NY-ESO-1 long peptides
72Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Overview of included studies (Continued)
Sabbatini 2013 RCT 888 NED after primary ther-
apy
CA-125 antibody versus placebo
Sandmaier 1999 uncontrolled phase
II
7 unknown Sialyl-Tn KLH conjugate
Schultes 1998 retrospective
uncontrolled
75 unknown CA-125 antibody
Ströhlein 2009 uncontrolled phase
I
2 progressive disease EpCAM or Her-2/Neu trifunctional antibody









Tsuda 2004 uncontrolled phase
I/II





5 residual or recurrent dis-
ease after prior chemo-
therapy
membrane folate receptor antibody
Vermeij 2012 uncontrolled phase
II
12 recurrent disease p53 long peptides
Wagner 1993 retrospective
uncontrolled
58 unknown CA-125 antibody

























































































yes yes yes no no yes
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9 yes no yes yes un-
known














9 yes no yes yes no yes yes yes no yes yes
Ehlen
2005
13 yes yes yes yes un-
known










no no no no yes no no no no
Gribben
2005
6 no no no yes un-
known
















5 no no no yes no yes yes yes no no no
Le
2012





yes yes no yes yes yes yes yes yes
74Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.





































no yes yes no yes no no yes no
Möbus
2003






no yes no yes yes yes no no no
Morse
2011
8 yes no no yes un-
known



















184 yes yes yes no un-
known
yes yes yes no no yes
Odunsi
2007
18 no no yes yes un-
known
















no yes no yes yes no no no no
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25 yes yes yes yes un-
known

























no yes yes no no yes
Ströhlein
2009
2 yes no no yes un-
known





no yes no no yes no no no no
Tsuda
2004







5 yes no yes yes un-
known
yes yes yes no yes yes
Vermeij
2012
12 yes no yes yes yes yes yes yes yes yes no
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no yes no no no no
a specified in clinical trial register, not in publication
Table 4. Evaluation of clinical responses to immunotherapy










45 yes both GCIG (evalu-
able patients
C1: 7, C2: 3)
C1: 7x , C2: 3x RECIST C1: 2x SD,
21x PD





















18/22 yes unknown unknown cCR 15x / 18x
Brossart
2000




9 yes both unknown unknown 1x NED, 8x
PD




6 yes unknown not reported
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Table 4. Evaluation of clinical responses to immunotherapy (Continued)
Diefenbach
2008
9 yes both unknown unknown not reported
Ehlen
2005





4x , 1x =, 6x unknown 3xSD, 10xPD
Freedman
1998




21 yes both GCIG 2x , 3x =, 16x
ˆ?
RECIST 14xSD, 7xPD 14xSD, 7xPD
Goh 2013 63 no
Gordon
2004
20 yes both unknown 6x unknown 2x NED, 2x




6 yes unknown 6x PD
Gulley 2008 3 yes both unknown unknown not reported
Heiss 2010 129 no
Imhof 2013 15 yes unknown not reproted
Kaumaya
2009
5 yes unknown 2x SD, 3x PD
Le 2012 2 yes tumour RECIST 2x PD 2x PD
Leffers
2009a
20 yes both GCIG not reported RECIST not reported 2x SD, 18xPD
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Table 4. Evaluation of clinical responses to immunotherapy (Continued)
Method
2002






14 yes unknown 1xSD, 11xPD
Morse 2011 8 no
Nicholson
2004
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Table 4. Evaluation of clinical responses to immunotherapy (Continued)
Sabbatini
2006




































38 yes tumour RECIST 1x CR, 2x PR,
10xSD, 9xPD








5 yes both unknown 1x , 1x =, 1x ,
2x unknown
unknown 1x NED, 1x





12 yes both GCIG 7x /=, 3x RECIST not reported 2x SD, 8x PD
Wagner
1993
58 yes CA-125 unknown not reported
C1 - cohort 1; l.f.u. - lost in follow-up; cCR - complete clinical remission; CR - complete response; PR - partial response; SD - stable
disease; PD - progressive disease; NED - no evidence of disease
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Table 5. Definitions and results of survival analysis in antigen-specific antibody studies
Study Analysed Definition Results
Baumann 2011 yes progression free survival/overall survival Median PFS: low dose 70 days (95% CI 63
to 91), high dose 68 days (95% CI 58 to 77)
Median OS: low dose 137 days (95% CI 99
to 218), high dose 185 (95% CI 134 to 472)
Berek 2001 yes time to relapse NS: median TTR placebo 11.3, robust
HAMA 16.4, and robust Ab2 18.9 months
Berek 2004 yes time to relapse/overall survival NS: TTR oregovomab 24.0 vs. placebo 10.
8 months (HR 0.543, 95% CI 0.287 to 1.
025); OS 57.5 oregovomab vs. 48.6 placebo
(HR 0.72, 95% C.I. 0.41 to 1.25)
Berek 2009 yes time to relapse (randomisation to relapse) NS: median TTR oregovomab 10.3 months
vs placebo 12.9 months
Braly 2009 yes progression free survival NS: median PFS simultaneous administra-
tion 17.9 months vs. delayed administration
16.1 months
Ehlen 2005 yes time to progression/survival (first dose to
death)
TTP median 8.4 weeks (range 2-61 weeks);
survival 37 weeks (range 11-110)
Gordon 2004 yes time to progression/survival (first dose to
death)
TTPmedian 11weeks (T-cells responders vs
non-responders P < 0.0001 HR 0.150, 95%
CI 0.006 to 0.168); survival median 70.4
weeks (T-cell responders vs non-responders
P < 0.002 HR 0.157, 95% CI 0.009 to 0.
347)
Heiss 2010 yes puncture free survival (first dose to therapeu-
tic puncture or death)/overall survival (first
dose to death)
Median puncture free survival: paclitaxel +
catumaxomab 52 days (95%CI 38-62) vs
catumaxomab 11 days (95% CI 9 to 20)
Median OS: paclitaxel + catumaxomab 110
days (95% CI 70 to 164) vs catumaxomab
81 days (95% CI 68 to 134)
Ma 2002 no
Method 2002 no
Möbus 2003 yes survival (first dose to death)/overall survival
(diagnosis to death)
survival median 16.8 months 95% CI 10.3
to 22.6 (Ab3 responders vs non-responders
18.2 vs 13.1, P = 0.0896; HAMA respon-
ders vs non-responders 22.6 months vs 7.6
months, P = 0.0016); overall survival me-
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Table 5. Definitions and results of survival analysis in antigen-specific antibody studies (Continued)
dian 34.4 months
Nicholson 2004 no
Noujaim 2001 yes survival (first dose to death) median survival & 3-year survival: Ab3 re-
sponders vs non-responders 22.9 vs 13.5
months, P = 0.0089 , 38% vs 8%; T-cell re-
sponders vs non-responders (n = 16) > 84 vs
13.2 months, P = 0.0202 , 75% vs 0%
Pfisterer 2006 no
Reinartz 2004 yes survival (first dose to death) median survival 19.4 months, Ab3 respon-
ders vs non-responders: 23.4 vs 4.9 months,
P < 0.0001
Sabbatini 2006 yes time to progression TTP: 4 months (95% CI 3-5 months)
Sabbatini 2013 yes recurrence free survival (randomisation to
recurrence)/overall survival (randomisation
to death)
median RFS: abagovomab 403 days (95%
CI 323 to 414) vs placebo 402 days (95%
CI 323 to 487)
2y OS rate: abagovomab 80% (SE 1.71) vs
placebo 80% (SE 2.43)
Schultes 1998 yes overall survival (diagnosis to death) median OS: robust Ab3 responders vs non-
robust responders 49 vs 38 months , P = 0.
0029; Ab2 robust vs non-robust responders
30.0 vs 44.0 months, P = 0.0475
Ströhlein 2009 yes overall survival not described separately for ovarian cancer
patients
van Zanten-Przybysz 2002 yes survival (first dose to death) median survival 22.0 months
Wagner 1993 yes not described survival robust Ab2 vs non-robust Ab2 re-
sponders NS
SE - standard error; RFS - recurrence free survival; OS - overall survival; TTR - time to relapse; PFS - progression free survival; TTP -
time to progression; HR - hazard ratio; CI - confidence interval
Table 6. Definitions and results of survival analysis in other antigen-specific immunotherapy studies
Study Analysed Definition Results
Berinstein 2012 yes time to progression (study day 0 to relapse) median TTP > 8 months (range 4 - >9)
Berinstein 2013 no
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Table 6. Definitions and results of survival analysis in other antigen-specific immunotherapy studies (Continued)
Brossart 2000 no
Chianese-Bullock 2008 no
Chu 2012 yes progression free survival (first vaccination to
relapse)/overall survival (first vaccination to
death/last follow-up)
3-yr PFS: arm 1 vs arm 2 40% vs 80% (p = 0.
17)
3yr OS: arm 1 vs arm 2 80% vs 100% (p = 1.
00)
Diefenbach 2008 yes time to progression (last chemo to relapse) median TTP 13.0 months (95%CI 11.2 - not
reached)
Dhodapkar 2012 no
Freedman 1998 yes progression free interval; survival median PFI 4 months (95% CI 1.9 to 7.6);
median survival 13.3. months (95% CI 1.5 to
30.8)
Galanis 2010 yes overall survival median OS 12.2 months (range 1.3-38.4)
Goh 2013 yes progression free survival; overall survival median PFS vaccine vs standard of care 365
days vs 321 days
OS: not reported
Gribben 2005 no
Gulley 2008 yes progression free survival; overall survival PFS: 9, 18, 19+ months; OS: 6, 19+, 21
months
Imhof 2013 yes time to progression (first vaccination to re-





Leffers 2009a yes disease specific survival (diagnosis to death of
ovarian cancer)
medianDSS participants vs historical controls
44.0 months vs 47.4 months
Letsch 2011 no
MacLean 1996 yes survival (trial entry to death) median survival 12.7 months
MacLean 1992 no
Mohebtash 2011 yes progression free survival/overall survival median PFS 2 months (range 1-36)
median OS 15.5 months (range 1.5-> 57.0)
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Table 6. Definitions and results of survival analysis in other antigen-specific immunotherapy studies (Continued)
Morse 2011 yes overall survival median OS not reached (range 289-1115+
days)
Nishikawa 2006 no
Odunsi 2007 yes time to progression (first vaccination to re-
lapse)
median TTP 19.0 months (95% CI 9.0 - not
reached)
Odunsi 2012 yes progression free survival / overall survival median PFS 21 months (95% CI 16 to 29
months)
median OS 48 months (95% CI not es-
timable)
Ohno 2009 no
Peethambaram 2009 yes time to progression median TTP 14.0 (range 12.1-18.3)
Rahma 2012 yes progression free survival (date on study to date
progression)
overall survival (date on study to date death
or last follow-up)
median PFS 4.2 vs 8.7 months
median OS 40.8 vs 29.6 months
Sabbatini 2000 yes time to progression (trial entry to relapse) median TTP 6 months (range 2-17)
Sabbatini 2007 yes time to progression (first vaccination to re-
lapse)
median TTP 4.2 months (95% CI 2.7 to 8.5)
Sabbatini 2012 yes time to progression no differences between cohorts (numbers not
reported)
Sandmaier 1999 no
Takeuchi 2013 yes overall survival median OS: HLA-A24 5 months (range 30-




TTR - time to relapse; TTP: time to progression; PFI - progression free interval; PFS - progression free survival; DFS - disease free
survival; CI - confidence interval; DSS - disease specific survival; OS - overall survival; SQ - subcutaneous; IV - intravenous
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Table 7. Definitions and results of anti-idiotypic (Ab2) humoral responses in antigen-specific monoclonal antibody studies
Study N Dose Target anti-
gen








Berek 2001 252 2 mg CA-125 no > 50 ng/mL 63% > 100 ng/mL
Berek 2004 145 2 mg CA-125 no > 100 ng/mL 67%
Berek 2009 371 2 mg CA-125 no unknown not reported unknown not reported
Braly 2009 40 unknown CA-125 yes > 100 ng/mL 94% vs 74%
Ehlen 2005 13 2 mg CA-125 yes > 50 ng/mL 45%
Gordon
2004
20 2 mg CA-125 yes > 50 ng/mL > 100 ng/mL 79%
Heiss 2010 129 10-20-50-
150 ug
EpCAM no
Ma 2002 4 unknown CA-125 no
Method
2002




44 2 mg CA-125 yes > 50 ng/mL 77%
Nicholson
2004
26 25 mg MUC1 yes unknown 100%
Noujaim
2001
184 2 mg CA-125 yes
Pfisterer
2006
36 2 mg CA-125 yes
Reinartz
2004
119 2 mg CA-125 yes
Sabbatini
2006
42 2 mg/0.2 mg CA-125 yes
Sabbatini
2013
888 2mg CA-125 no
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58 1 mg CA-125 no >0 u/l 64% > 10 u/l 32%
Table 8. Definitions and results of anti-anti-idiotypic (Ab3) humoral responses in antigen-specific antibody studies
Study N Dose Target anti-
gen








Berek 2001 252 2 mg CA-125 no
Berek 2004 145 2 mg CA-125 no
Berek 2009 371 2 mg CA-125 no
Braly 2009 40 unknown CA-125 no
Ehlen 2005 13 2 mg CA-125 yes > 100 ng/mL > 3x baseline 0%
Gordon
2004
20 2 mg CA-125 yes > 100 ng/mL > 3x baseline 10,5%
Heiss 2010 129 10-20-50-
150 µg
EpCAM no
Ma 2002 4 unknown CA-125 no
Method
2002
102 2 mg CA-125 no
Möbus
2003
44 2 mg CA-125 yes > 3x baseline 28%
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184 2 mg CA-125 yes > 3x baseline 43%
Pfisterer
2006




119 2 mg CA-125 yes > 1000 u/mL 68%
Sabbatini
2006
42 2 mg/0.2 mg CA-125 yes > 1000 u/mL 100%
Sabbatini
2013






















58 1 mg CA-125 no
Table 9. Definitions and results of humoral response evaluation in other antigen-specific immunotherapy studies
Study N Target antigen(s) Analysed Assay Positive if: % positive









Berinstein 2013 19 survivin no
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Table 9. Definitions and results of humoral response evaluation in other antigen-specific immunotherapy studies (Continued)













6 NY-ESO-1 yes unknown unknown not reported
Dhodapkar
2012
9 NY-ESO-1 yes ELISA >100 0%
Freedman 1998 21 CEA yes ELISA ≥2x pretreatment & > mean
+ 2SD of 10 normal sera
0%
Galanis 2010 63 MUC1 yes unknown unknown 0%
Goh 2013 6 CYP1B1 no
Gribben 2005 3 CEA, MUC1 no
Gulley 2008 30 Sialyl Tn no
Imhof 2013 15 TERT, survivin no
Kaumaya 2009 5 Her-2/neu yes ELISA high response: > 0.6
intermediate response: 0.2-0.
6
60% high responses, 40% in-
termediate responses
Le 2012 2 mesothelin no
Leffers 2009a 20 p53 yes unknown unknown pre-imm: 40%, post-imm:
45%
Letsch 2011 8 WT1 no
MacLean 1996 10 Thomson Frieden-
reich
yes ELISA unknown 80% IgA, 90% IgM, 90%
IgG, 0% IgE
MacLean 1992 34 Sialyl Tn yes ELISA unknown 96%
Mohebtash 2011 14 MUC1, CEA no




88Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 9. Definitions and results of humoral response evaluation in other antigen-specific immunotherapy studies (Continued)
A, Abl-binding pro-
tein 3c, cyclin I,
toposiomerase IIα/




Nishikawa 2006 4 NY-ESO-1 no
Odunsi 2007 18 NY-ESO-1 yes ELISA unknown 22%
Odunsi 2012 22 NY-ESO-1 yes ELISA unknown 50%
Ohno 2009 6 WT1 no
Peethambaram
2009
4 Her-2/neu yes ELISA unknown unknown
Rahma 2012 21 p53 no
Sabbatini 2000 25 Lewis Y yes ELISA unknown 67%
Sabbatini 2007 11 GM2, Globo-
H, Lewis Y, Tn-
MUC1, Tn(c) sTN
(c), TF(c)
yes ELISA negative to ≥ 1:40 or 8-fold
increase
89% ≥3 antigens; 22%
GM2, 33% Globo-H, 11%
Lewis Y, 100% Tn-MUC1,
44% Tn(c), 44% sTN(c),
78% TF(c)
Sabbatini 2012 28 NY-ESO-1 yes ELISA ≥100 C1: 25%,C2: 46%,C3: 91%
Sandmaier 1999 7 Sialyl Tn yes ELISA ≥1:20 100% IgM, 80% IgG








Tsuda 2004 5 patient-tailored
cocktail
yes ELISA unknown 67%
Vermeij 2012 12 p53 no
C1 - cohort 1
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Table 10. Definitions and results of cellular responses in antigen-specific antibody studies








Berek 2001 252 2 mg CA-125 no
Berek 2004 145 2 mg CA-125 no
Berek 2009 371 2 mg CA-125 no
Braly 2009 40 unk CA-125 yes ELISPOT permutation test 44% vs. 21%
Ehlen 2005 13 2 mg CA-125 yes ELISPOT permutation test n = 4 CA-125:
75%; n = 3 ore-
govomab 67%
Gordon 2004 20 2 mg CA-125 yes ELISPOT permutation test n = 18 CA-125:
39%; n = 18 ore-
govomab 50%; n
= 8 autologous tu-
mour cells 63%
Heiss 2010 129 10-20-5-150
µg
EpCAM no
Ma 2002 4 unk CA-125 yes proliferation assay unknown n = 4: 50%
Method 2002 102 2 mg CA-125 yes ELISPOT not reported not reported
Möbus 2003 44 2 mg CA-125 no
Nicholson
2004
26 25 mg MUC1 no
Noujaim
2001








n = 17 CA-
125 53%; Th1 cy-
tokines 41%, Th2
cytokines 94%





L vs S: n = 12 vs
17, CD4: 58% vs
29%; CD8 75%
vs 18%
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Table 10. Definitions and results of cellular responses in antigen-specific antibody studies (Continued)
Reinartz 2004 119 2 mg CA-125 no
Sabbatini
2006
42 2 mg/0.2 mg CA-125 yes ELISPOT spots experimen-
tal wells - control
wells > 20 & ex-
perimental wells/
control wells > 1.
5x
n = 5: 80%
Sabbatini
2013
888 2 mg CA-125 yes not reported not reported









unknown EpCAM n = 1
(100%)




5 50 mg membrane
folate receptor
yes proliferation assay unknown 0%




Table 11. Definitions and results of cellular responses in other antigen-specific immunotherapy studies
Study N Target antigen(s) Analysed Assay Positive if: % positive










> 2x increase of pen-
tamer positive CD8-
cells
83% against at least 1
peptide





C2+C3: 92% on ≥ 2
assays




unknown n = 1: Her-2/Neu
100%; n = 2 MUC1
50%
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yes ELISPOT (CD8) unknown n = 9: FBP 40%, Her-
2/neu 83%, MAGE-
A1 83%



















9 NY-ESO-1 yes ELISPOT / Tetramer
staining (CD8)
specific spots > 30
and > 3x spots ir-
relevant control > 0.
1% tetramer positive
CD8-cells
both assays n = 9: 67%
Freedman 1998 30 Sialyl Tn no
Galanis 2010 21 CEA no
Goh 2013 63 MUC1 yes unknown not reported
Gribben 2005 6 CYP1B1 yes ELISPOT spots minus neg-
ative control>20 / 106
PBMC & >2x baseline
n = 5: 20%
Gulley 2008 3 CEA, MUC1 yes ELISPOT (CD8) /
IFN-γ ELISA (CD4)
ELISPOT:≥2-fold in-




n = 3: 100% CEA
n = 3: 33% CEA
Imhof 2013 15 TERT, survivin yes intracellular cytokine
staining
unknown overall > 90%
Kaumaya 2009 5 Her-2/neu no
Le 2012 2 mesothelin yes ELISPOT (CD8) specific spots >2x base-




lin specific CD8 cells
present
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Table 11. Definitions and results of cellular responses in other antigen-specific immunotherapy studies (Continued)




- specific spots≥ 10/10
5 PBMC & ≥ 3x pre-
immunization
- cpm > 1000/minute,




n = 18: 100%
n = 17: 82%
n = 5: CD8 0%, CD4
100%
Letsch 2011 8 WT1 yes tetramer staining unknown not reported
MacLean 1996 10 Sialyl Tn no
MacLean 1992 34 Thomson Frieden-
reich
no
Mohebtash 2011 14 MUC1, CEA yes ELISPOT (CD8) ≥2x pre-
immunization








tein 3c, cyclin I,
toposiomerase IIα/




yes ELISPOT >40 spots / 106 PBMC
over prevaccination
n = 8: 63%
Nishikawa 2006 4 NY-ESO-1 yes ELISPOT (CD4) unknown n = 4: 75%
Odunsi 2007 18 NY-ESO-1 yes ELISPOT (CD4/
CD8)
mean ± 3 SD n = 18: CD4 - 83%,
CD8 - 33%






Ohno 2009 6 WT1 no
Peethambaram
2009
4 Her-2/neu yes proliferation assay
ELISPOT assay
unknown not reported separately
for ovarian cancer pa-
tients
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Table 11. Definitions and results of cellular responses in other antigen-specific immunotherapy studies (Continued)




C1: 64%, C2: 83%
Sabbatini 2000 25 Lewis Y no
Sabbatini 2007 11 GM2, Globo-




Sabbatini 2012 28 NY-ESO-1 yes ELISPOT (CD4/
CD8)
>50 spots / 5x104 cells
& >3x unstimulated
cells
CD4: 100% in C1/
C2/C3
CD8: C1 0%, C2
62%, C3 92%
Sandmaier 1999 7 Sialyl Tn yes proliferation assay* > upper limit of nor-
mals (SI 2.35)
n = 4: 50%







yes unknown unknown inadequately reported
Tsuda 2004 5 patient-tailored
cocktail
yes IFN-γ ELISA unclear n = 2 after 6 vacc.
100%; n = 1 after 12
vacc. 100%
Vermeij 2012 12 p53 yes ELISPOT
proliferation assay
- specific spots≥ 10/10
5 PBMC & ≥ 3x pre-
immunization
- cpm > 1000/minute,
SI≥3 and≥ 2x pre im-
munization
90% after 2 vacc, 87.
5% after 4 vacc.
80% after 2 vacc, 62.
5% after 4 vacc.
* as measured after at least three immunizations; SI - stimulation index; SD - standard deviation; C1 - cohort 1
Table 12. Definitions and results of human-anti-mouse antibody (HAMA) evaluation in antigen-specific antibody studies
Study N Dose Target anti-
gen







EpCAM yes unknown C1 61%, C2
100%
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Table 12. Definitions and results of human-anti-mouse antibody (HAMA) evaluation in antigen-specific antibody studies
(Continued)
Berek 2001 252 2 mg CA-125 yes > 5000 ng/mL 51%
Berek 2004 145 2 mg CA-125 yes > 200 ng/mL unknown > 5000 ng/mL 59%
Berek 2009 371 2 mg CA-125 yes unknown n.r.
Braly 2009 40 unk CA-125 yes unknown SIM vs OWD:
100% vs 80%
> 3000 ng/mL SIM vs OWD:
88% vs 74%
Ehlen 2005 13 2 mg CA-125 yes > 200 ng/mL 100% > 5000 ng/mL 58%
Gordon
2004
20 2 mg CA-125 yes > 200 ng/mL unknown > 5000 ng/mL 79%
Heiss 2010 129 10-20-50-
150 µg
EpCAM yes unknown not reported
Ma 2002 4 unk CA-125 no
Method
2002




44 2 mg CA-125 yes > 5000 ng/mL 68%
Nicholson
2004
26 25 mg MUC1 no
Noujaim
2001
184 2 mg CA-125 no
Pfisterer
2006




119 2 mg CA-125 yes > 100 ng/mL 78%
Sabbatini
2006
42 2 mg/0.2 mg CA-125 yes > 100 ng/mL 90%
Sabbatini
2013











yes unknown 100% (n = 1)
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58 1 mg CA-125 no
n.a. - not applicable; n.r. - not reported
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Ovarian Neoplasms] explode all trees
#2 ovar* near/5 (cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan*)
#3 #1 or #2
#4 MeSH descriptor: [Immunotherapy, Active] explode all trees
#5 MeSH descriptor: [Cancer Vaccines] explode all trees
#6 immunotherapy or vaccination* or vaccine* or immunization or immunisation
#7 #4 or #5 or #6
#8 MeSH descriptor: [Antigens, Neoplasm] explode all trees
#9 antigen*
#10 #8 or #9
#11 MeSH descriptor: [T-Lymphocytes] explode all trees
#12 (T cell*) or T-cell* or (T lymphocyte*) or T-lymphocyte* or CD4* or CD8*
#13 #11 or #12
#14 #3 and #7 and #10 and #13
Appendix 2. MEDLINE search strategy
MEDLINE Ovid
1 exp Ovarian Neoplasms/
2 (ovar* adj5 (cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan*)).mp.
3 1 or 2
4 exp Immunotherapy, Active/
5 Cancer Vaccines/
6 (immunotherapy or vaccination* or vaccine* or immunization or immunisation).mp.
7 4 or 5 or 6
8 exp Antigens, Neoplasm/
9 antigen*.mp.
10 8 or 9
11 exp T-Lymphocytes/
12 (T cell* or T-cell* or T lymphocyte* or T-lymphocyte* or CD4* or CD8*).mp.
13 11 or 12
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14 3 and 7 and 10 and 13
key:
mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supple-
mentary concept, unique identifier
Appendix 3. EMBASE search strategy
EMBASE Ovid
1 exp ovary tumor/
2 (ovar* adj5 (cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan*)).mp.
3 1 or 2
4 active immunization/
5 cancer vaccine/
6 (immunotherapy or vaccination* or vaccine* or immunization or immunisation).mp.
7 4 or 5 or 6
8 exp tumor antigen/
9 antigen*.mp.
10 8 or 9
11 exp T lymphocyte/
12 (T cell* or T-cell* or T lymphocyte* or T-lymphocyte* or CD4* or CD8*).mp.
13 11 or 12
14 3 and 7 and 10 and 13
key:
mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword
Appendix 4. Data extraction form
CRITICAL REVIEW & DATA EXTRACTION FORM






Publication Type Journal / Abstract / other (specify)
Study Characteristics*
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Participants · Total number of participants: ………………
· Number of patients with EOC: …………….
· Age:
o Median + range: ……………………
o Mean + SD: …………………………
· FIGO stage: …………………………………
· Histological tumor type: ……………………
· Tumour grade: ………………………………
· Previous therapy: ……………………………
· Concurrent therapy: ………………………..
Trial intervention · type of vaccine: ………………………………
· antigen used: …………………………………
· adjuvant used: ……………………………….
· route of vaccination: …………………………
· vaccination schedule: ……………………….
Outcomes
Trial N + reason
Patients excluded during trial
Patients lost to follow-up
Clinical responses N
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(Continued)
Postimmunotherapy treatment Administered: Yes ? No ?


















Separate information on cytotoxic T-lymphocytes and Thelper lymphocytes available: Yes ? No ?
If yes, specify: ………………………………………………………………………
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Adverse events
Type of AE’s · Local events (injection site): Yes ? No ?
If yes, specify: …………………
· Systemic: Yes ? No ?
If yes:
Autoimmunity Yes ? No ?
If yes, specify: ……………………………
Allergic reactions Yes ? No ?
If yes, specify: ……………………………
Other Yes ? No ?
If yes, specify: ……………………………
Other
Contact with primary investigators Clarify Methods ?
Clarify Results ?
Notes
WH A T ’ S N E W
Date Event Description
8 September 2014 Amended Author details amended
31 July 2014 New search has been performed Searches re-run October 2013. New studies included
and excluded
10 July 2014 New citation required but conclusions have not
changed
The text of the review was updated to reflect addi-
tional studies included and excluded. Overall, conclu-
sions unchanged
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C O N T R I B U T I O N S O F A U T H O R S
NL selected relevant studies, assessed study quality, extracted data and wrote the review. HWN selected relevant studies, assessed study
quality and extracted data. TD andWH checked all rejected titles and resolved any disagreements on study selection and data extraction.
HMB and BC provided statistical and methodological support. KM supported in writing the review as an expert in immunology.
D E C L A R A T I O N S O F I N T E R E S T
Ninke Leffers, Cornelis Melief, Toos Daemen and Hans Nijman were investigators in two studies included in this review (Leffers 2009a;
Vermeij 2012). No potential conflicts of interest exist for the other contributing authors.





D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
TD was added to the team. For the update of the review, we used The Cochrane Collaboration’s Risk of bias’ tool to assess the risk of
bias in randomised controlled trials, whereas in the protocol and the previous version of the review the Delphi list was used. There are
no further relevant differences between protocol and review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibodies, Monoclonal [adverse effects; therapeutic use]; CA-125 Antigen [immunology]; Clinical Trials, Phase I as Topic; Clinical
Trials, Phase II as Topic; Immunotherapy, Active [adverse effects; ∗methods]; Molecular Targeted Therapy [methods]; Neoplasms,
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